

# Human Medicines Regulations 2012

## Advisory Bodies

Commission on Human Medicines

Annual Report 2023

Published July 2024





**Medicines and Healthcare products Regulatory Agency**

**HUMAN MEDICINES REGULATIONS 2012  
ADVISORY BODIES**

**Commission on Human Medicines**

**ANNUAL REPORT  
2023**

**Laid before Parliament pursuant to  
Part 2, Regulation 12(4) of  
the Human Medicines Regulations 2012**



© Crown copyright 2024

Published by the Medicines and Healthcare products Regulatory Agency

This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit [nationalarchives.gov.uk/doc/open-government-licence/version/3](https://nationalarchives.gov.uk/doc/open-government-licence/version/3).

Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

This publication is available at <https://www.gov.uk/mhra>

Any enquiries regarding this publication should be sent to the Medicines and Healthcare products Regulatory Agency at:

Medicines and Healthcare products Regulatory Agency

Customer Services

10 South Colonnade

Canary Wharf

London E14 4PU

Tel: 020 3080 6000

E-mail: [info@mhra.gov.uk](mailto:info@mhra.gov.uk)

ISBN 978-1-8384147-3-3

Printed on paper containing 40% recycled fibre content minimum

Printed in the UK by HH Associates Ltd. on behalf of the Controller of His Majesty's Stationery Office

# Table of Contents

<b>Foreword by the Secretary Of State For Health and Social Care</b> .....	7
<b>Commission on Human Medicines</b> .....	8
<b>Annual Report - 2023</b> .....	9
About the Commission on Human Medicines .....	9
<b>Chair’s perspective on the year - Professor Sir Munir Pirmohamed</b> .....	10
Safety of Medicines .....	13
Highlights of our 2023 achievements .....	14
Breakdown of advice provided by the Commission on Human Medicines, Expert Advisory Groups (EAG), Expert Working Groups (EWG) in 2023 .....	15
Membership .....	16
Costs.....	16
Code of Practice for the Commission on Human Medicines and other expert advisory committees	17
Membership of the Commission on Human Medicines (CHM) .....	18
CHM Invited Experts and Observers .....	20
Membership of the Cardiovascular, Diabetes, Renal, Respiratory & Allergy Expert Advisory Group (CDRRA EAG) .....	22
Membership of the Chemistry, Pharmacy and Standards Expert Advisory Group (CPSEAG) ...	23
Membership of the Clinical Trials, Biologicals & Vaccines Expert Advisory Group (CTBVEAG)	25
Membership of the Gastroenterology, Rheumatology, Immunology & Dermatology Expert Advisory Group (GRIDEAG) .....	26
Membership of the Infection Expert Advisory Group (IEAG).....	27
Membership of the Medicines for Women’s Health Expert Advisory Group (MWHEAG).....	29
Membership of the Neurology, Pain & Psychiatry Expert Advisory Group (NPPEAG) .....	31
Membership of the Oncology & Haematology Expert Advisory Group (OHEAG) .....	32
Membership of the Paediatric Medicines Expert Advisory Group (PMEAG) .....	33
Membership of the Pharmacovigilance Expert Advisory Group (PEAG) .....	35
Membership of the CHM’s Cancer Vaccines Expert Working Group .....	37
Membership of the CHM’s Isotretinoin Implementation Expert Working Group.....	40
Membership of the Real World Data Ad Hoc Group .....	41
Membership of the Topiramate Implementation Expert Working Group.....	42
Membership of the Valproate Epigenetics Expert Working Group .....	43
Membership of the CHM’s Valproate Implementation Working Group .....	44
Membership of the COVID-19 Vaccine Benefit Risk Expert Working Group .....	45
Membership of the COVID-19 Therapeutic Expert Working Group.....	48
<b>ANNEX A - DECLARATION OF INTERESTS</b> .....	51



# **Foreword by the Secretary Of State For Health and Social Care**

It gives me great pleasure to present the annual reports for 2023 of the Human Medicines Regulations Advisory Bodies: The Commission on Human Medicines. These reports include a record of members' interests in the relevant industry as per the Conflicts of Interest Code of Practice.

On behalf of all Health Ministers, I would like to thank the Chairs and Members of the Commission and all those who contribute to their many Expert Advisory Groups and Expert Working Groups whose professional expertise, commitment and hard work plays a vital role in ensuring that the medicinal products we take continue to meet the highest standards of safety, quality and efficacy.

Wes Streeting MP

# Commission on Human Medicines



# Annual Report - 2023

## About the Commission on Human Medicines

The Commission on Human Medicines (CHM) is an advisory non-departmental public body, sponsored by the [Department of Health and Social Care](#) (DHSC). The CHM was established in 2005 to advise ministers and the Licensing Authority, [Medicines and Healthcare products Regulatory Agency](#) (MHRA), on the safety, efficacy and quality of medicinal products.

The functions of the CHM are set out in Regulation 10 of the Human Medicines Regulations 2012 (SI 2012/1916). This report presents a summary of the work undertaken by CHM in 2023.

The functions of the CHM are:

- to advise the Health Ministers and the Licensing Authority (LA) on matters relating to human medicinal products including giving advice in relation to the safety, quality and efficacy of human medicinal products where either the Commission thinks it appropriate or where it is asked to do so;
- to consider those applications where the LA has a statutory duty to refer to the CHM or chooses to do so;
- to consider representations made (either in writing or at a hearing) by an applicant or by a licence or marketing authorisation holder in certain circumstances;
- to promote the collection and investigation of information relating to adverse reactions to human medicines for the purposes of enabling such advice to be given.

## Chair's perspective on the year - Professor Sir Munir Pirmohamed

The CHM depends heavily on the dedication, knowledge and experience of its experts and the considerable efforts from all experts are greatly appreciated and valued. The immense contribution of CHM's experts has ensured pragmatic advice to the MHRA and the Health Ministers, based on rigorous examination of scientific data leading to regulatory decisions translated effectively into clinical practice and a direct benefit to patients.

In 2023, CHM continued to carefully consider the data on quality, efficacy & safety of a number of new active substances and after detailed deliberations on diverse issues, advised the MHRA on the approvability of these new medicines. Salient examples of new medicines include:

- **Casgevy** (exagamglogene autotemcel), a gene therapy product based on innovative gene-editing CRISPR tool for treatment of sickle-cell disease and transfusion dependent  $\beta$ -thalassaemia, which was approved first in the UK before any other country in the world.
- **Ebvallo** (tabelecleucel), indicated for treatment of adult and paediatric patients with relapsed or refractory Epstein-Barr virus positive posttransplant lymphoproliferative disease.
- **Tepkinly** (epcoritamab), a bispecific antibody for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
- **Litfulo** (ritlecitinib), an enzyme inhibitor that reduces the activity of enzymes called JAK3 and TEC kinase, for severe alopecia areata in adults and adolescents 12 years of age and older.
- **Jesduvroq** (Daprodustat) for treatment of adult patients with anaemia associated with chronic kidney disease.

Examples of other applications where the CHM provided significant advice to the MHRA include:

- **Abrysvo**, a respiratory syncytial virus (RSV) vaccine on which the CHM advised on the appropriate gestational age when it should be used in pregnant women based on the evidence generated and taking in to account the UK clinical practice setting.

Although the public health emergency due to COVID has passed, there is still a need for COVID vaccines and therapeutics to prevent and treat infections with either the original strain of virus or the different emerging strains of the COVID virus and to include broader populations in the indication than originally authorised. And in this regard, the CHM has advised on the following:

- **SKYCovion COVID-19 vaccine** (recombinant, adjuvanted) a national application for a COVID-19 vaccine targeting the ancestral D614G strain to be used for primary immunisation in adults in other regions by World Health Organization (WHO), where MHRA provided the regulatory support on the advice of the CHM
- A line extension (significant modification of the existing product such as adding new strength or to act against new strains) of COVID vaccines viz. Comirnaty original/Omicron BA.4-5 (Tozinameran 5 mcg/Famotizonaeran 5 mcg) for active

immunization to prevent COVID-19 in children aged 5 to 11 years who have previously received a primary vaccination course.

- A line extension of COVID vaccines to include new strains viz Spikevax bivalent original/Omicron BA.4-5 (Elasomeran and Davesomeran) for active booster immunization to prevent COVID-19 in individuals 12 years of age and older who have previously received at least a primary vaccination course.
- Other line extensions / variations of COVID vaccines include extension of use of a booster of Spikevax original and Spikevax bivalent original/BA.1. to children aged 6-11 years old, and
- Spikevax COVID-19 (XBB.1.5) for active immunisation to prevent COVID-19 in individuals 6 months of age and older.

In addition to advising on new medicines, the CHM have also advised on the safety and effectiveness of already approved medicines for use in new indications or continued approvability of medicines approved under conditional marketing authorisation based on evaluation of the emerging evidence on benefit and safety. Salient examples of such applications include:

- **Mounjaro** (tirzepatide) - The Commission considered and discussed the variation application for tirzepatide (which was already approved for treatment of Type 2 diabetes mellitus) for a new use in the treatment of weight management and advised the grant of the variation to the Marketing Authorisation for Mounjaro.
- Another significant variation was the approval of an extension of indication for **Symbicort 200/6 Turbohaler** (budesonide and formoterol fumarate), which was already approved for regular maintenance treatment of asthma. The new indication is for it to be used 'as needed' treatment of patients with mild asthma.
- **Levosert** (Levonorgestrel) intra-uterine delivery system and Mirena intra-uterine delivery system which were approved for use as contraception for up to 5 years, and varied to extend the duration of use as contraception to 8 years.
- Other examples include **Brukinsa** (zanubrutinib) which was previously approved for the treatment of Waldenström's macroglobulinaemia, marginal zone lymphoma and chronic lymphocytic leukemia, was proposed for treatment in the new indication of adult patients with refractory or relapsed follicular lymphoma.
- The CHM also considered the emerging evidence on conditional marketing authorisation of **Adakveo** (Crizanlizumab) and advised that its license should be revoked and not renewed.

The Early Access to Medicines Scheme (EAMS) helps to give people with life threatening or seriously debilitating conditions, early access to new medicines that do not yet have a marketing authorisation, where there is a clear unmet medical need. CHM advised the MHRA on EAMS applications, notably:

- **Glofitamab** for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
- **Dostarlimab** for patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer.

The MHRA offers incentives in the form of market exclusivity and full or partial refunds for marketing authorisation fees to encourage development of medicines in rare diseases. CHM advises MHRA on Orphan designation applications and whether the medicine, its effects and the medical condition meets the criteria. The CHM considered and discussed the eligibility of products for orphan designation and over the last year advised on the grant of Orphan designation for products which include:

- **Voraxaze** (glucarpidase) to reduce toxic plasma methotrexate concentrations.
- **Pombiliti** (cipaglucosidase alfa) for treatment of adults with late-onset Pompe disease.
- **Nexviadyme** (avalglucosidase alfa) for treatment of Pompe disease.

Reclassification of medicines involves switching the legal status of medicines between Prescription-only medicines (POM), Pharmacy medicines (P) and General sales list medicines (GSL). New medicines are generally approved as 'prescription-only medicines' but overtime, growing confidence of the medicine's role and improved understanding of its side effects can lead to switches to Pharmacy or General Sales list which empowers patients' ability to self-care and alleviate the demand for NHS services. The CHM considered the evidence and justifications supporting the applications for reclassification and advised on reclassification of medicines; examples include:

- **Flurbiprofen oromucosal spray** from POM to P which will improve access of medicines to patients by enabling pharmacists to support the management of certain conditions (acute sore throat in adults).
- Based on the evidence derived from a consultation, the CHM considered that **codeine linctus** is being incorrectly used, can lead to addiction and is used for illegal purposes and therefore the CHM advised that codeine linctus *is frequently and to a very wide extent used incorrectly, and as a result is likely to present a direct or indirect danger to human health* and should be reclassified to POM.

The CHM also advised on the approvability of several established medicine applications. Established medicines constitute the majority of the medicines used in the UK so the licensing authority needs to ensure patients and prescribers in UK have access to safe and effective medicines of good quality. The advice from CHM in relation to such products included a wide range of topics, from balance in weight of benefits as compared against the risks to the acceptable intake levels of nitrosamine impurities that could be permitted in different medicines.

The CHM also provided clinical advice and support to the MHRA in shaping the regulatory strategies for the Innovative Licensing and Access Pathway (ILAP) and to inform the risk-proportionate approaches to assessment of clinical trials and established medicines. In order to support the development of cancer vaccines, the CHM also recommended the creation of a Cancer Vaccine Expert Working Group to consider the new approaches such products will require.

The CHM discussed the merits and advantages and the potential risks of non-medical prescribing for biomedical scientists and clinical scientists. The CHM provided their advice to DHSC on what medicines could be safely prescribed by these groups currently and the measures that could be taken to allow these groups to prescribe more medicines in the future.

## Safety of Medicines

The CHM advised on a range of issues relating to the safety of medicines over the course of the year, including:

- At multiple meetings, the CHM considered the safety of **valproate**, a medicine used to treat epilepsy and bipolar disorder, and gave advice on newly available study data.
- The CHM considered and advised on safety data and the ongoing monitoring of safety for vaccines against **COVID-19**, **monkeypox**, and **herpes zoster** (the virus that causes shingles).
- There were two medicines, **loperamide** and **codeine linctus**, for which CHM considered data on risks associated with their misuse and gave advice on the availability of these medicines in view of these risks.

Patient views are essential in decision-making on the safety of medicines. In 2023, the CHM directly heard patients' and patient representatives' perspectives on long-lasting or potentially disabling adverse effects of fluoroquinolone antibiotics, and on withdrawal reactions with steroid medicines used on the skin.

The CHM, as per the terms of reference, also has a duty to ensure that information relating to adverse reactions was collected and scrutinised throughout 2023. The CHM take assurance that the MHRA has systems in place for reporting of suspected adverse drug reactions and for review of these and other reports. However, the CHM continues to have an important role in giving independent advice on these safety data where needed.

# Highlights of our 2023 achievements

Authorisation of safe and effective new medicines is central to advancing public health as they offer new opportunities for treating certain diseases. In 2023:

The CHM was asked to advise on **187** papers over 12 meetings, the details of these are:

## Groups seeking advice

**163** of the papers were from licensing group

**18** of the papers were from post-licensing group

**6** of the papers were from clinical trials group

## Type of Product

**141** papers concerned Chemical products

**33** were Biological products

**13** were papers not related to any products

## Stage of advice

**80** papers were preliminary advice on applications

**85** papers were final advice on applications

**22** papers were on strategy and/or process

The above papers included

- **226** products (some papers would have covered multiple products such as safety of a class of medicine and different strength of the same medicine will be considered a different product).
- **5** papers under the Early Access to Medicines Scheme

Additionally, 3 ad-hoc/extraordinary meetings were held by the CHM to discuss urgent matters such as valproate and COVID-19 vaccines.

**Once a medicine has been authorised, the CHM is assured that MHRA continuously monitor the quality, safety and efficacy of the medicine to keep patients safe.**

\* The licensing authority seeks advice from the CHM by the form of a “paper”. A paper may cover a number of products, either pre-licensing or post-licensing, to ask for CHM’s preliminary or final advice. In 2023, three of the 12 meetings were two-day meetings. Preliminary Advice is CHM’s provisional opinion on the product concerned, as described in Schedule 11 of the HMR. CHM’s recommendation is final following representations made by the applicant (Sch 11 of the HMR).

## Breakdown of advice provided by the Commission on Human Medicines, Expert Advisory Groups (EAG), Expert Working Groups (EWG) in 2023

CHM, Expert Advisory Groups and Expert Working Groups	Abbrev.	Papers Considered and Advice Given	
		by meeting	by writing
Commission on Human Medicines	CHM	187	2
Chemistry, Pharmacy and Standards	CPS EAG	105	-
Clinical Trials, Biologicals & Vaccines	CTBV EAG	1	7
Pharmacovigilance	P EAG	35	-
Cardiovascular, Diabetes, Renal, Respiratory and Allergy	CDRRA EAG	5	1
Gastroenterology, Rheumatology, Immunology & Dermatology	GRID EAG	4	-
Paediatric Medicines	PM EAG	20	2
Oncology and Haematology	OH EAG	13	2
Neurology, Pain & Psychiatry	NPP EAG	4	-
Medicines for Women's Health	MWH EAG	12	2
Cancer Vaccines Expert Working Group		9	-
COVID-19 Therapeutic Expert Working Group		2	-
COVID-19 Vaccines Benefit Risk Expert Working Group		10	-
Isotretinoin Implementation Expert Working Group		18	-
Real World Data Ad Hoc Group		1	-
Topiramate Implementation Expert Working Group		4	-
Valproate Epigenetics Expert Working Group		5	-
Valproate Implementation Expert Working Group		17	1
<b>Total Papers Considered and Advice Given</b>		<b>426</b>	

Summary reports based on the minutes of each meeting from the CHM's Expert Advisory Groups are published on the [GOV.UK](https://www.gov.uk) website.

## Membership

Chair and Members of the Commission on Human Medicines are appointed under Regulation 9 of the Human Medicines Regulations 2012, and are expected to abide by the [Code of Conduct for Board Members of Public Bodies](#) and [Governance Code for Public Appointments](#), as part of their terms and conditions of appointment. Chairs and Members of the expert advisory groups and working groups are also expected to abide by the [Code of Practice for Scientific Advisory Committees](#).

The CHM has 22 members (including the Chair) appointed by Ministers and meets 12 times a year for up to two days. The work of the CHM is supported by ten established Expert Advisory Groups (EAGs) as well as eight Expert Working Groups (EWG) comprising of 206 experts.

EWGs are created at the request of the Licensing Authority and/or the CHM to advise the CHM on particular issues. The CHM wishes to record its gratitude and appreciation of the valuable work of its Expert Advisory Groups and Working Groups. Details of members of the CHM, its expert advisory groups and working groups are listed in this report.

## Costs

Commissioners are entitled to claim an attendance fee of £325 per day or a Chair's fee of £500. Expert Advisory Group members are entitled to claim an attendance fee of £200 or a Chair's fee £325. Travel and subsistence are also payable within standard Department of Health & Social Care guidelines.

If you are interested in learning more about CHM's you can find further information on the Gov.uk website: <https://www.gov.uk/government/organisations/commission-on-human-medicines>



## Code of Practice for the Commission on Human Medicines and other expert advisory committees

All chairs, members, co-opted members and invited and patient experts of all our scientific advisory committees are required to declare any personal and non-personal interest, or any significant interests held by close family or friends, which may be reasonably perceived to influence their judgement in performing their functions and obligations.

Furthermore, all chairs and members must declare their interest in any items being discussed at meetings and will declare any new conflict of interest at the earliest opportunity in advance of the next meeting they attend and openly at that next meeting. These are recorded in the published meetings. Where a member declares a potential conflict at meetings, it is recorded in the minutes and the member takes no part in the meeting for the duration of that item of discussion.

The principles in the Code also apply to observers and invited experts who are asked to contribute written advice and do not attend committee meetings.

The Code of Practice is published on:

[https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/1103036/2022.09.07\\_The\\_Code.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1103036/2022.09.07_The_Code.pdf)

The list of declared interests for chairs and members of CHM (and EAGs, EWGs and ad-hoc groups) is available below.

## Membership of the Commission on Human Medicines (CHM)

Post	Name and title	Affiliations (if applicable)
<b>Chair</b>	<b>Professor Sir Munir Pirmohamed</b> MB ChB (Hons) PhD FRCP FRCP (Edin) FBPhS, FFPM (Hon) FMedSci	David Weatherall Chair of Medicine, University of Liverpool, NHS Chair of Pharmacogenetics, Director of the Wolfson Centre for Personalised Medicine, Director of the Centre for Drug Safety Science
<b>Vice Chair</b>	<b>Professor Steven Cunningham</b> MBChB PhD FRCPCH	Professor of Paediatric Respiratory Medicine, University of Edinburgh and Honorary Consultant, Royal Hospital for Children and Young People, NHS Lothian, Edinburgh
<b>Member</b>	<b>Professor Amanda Adler</b> MD PhD FRCP	Professor of Diabetic Medicine and Health Policy, University of Oxford
<b>Member</b>	<b>Professor Jamie Coleman</b> MD MA (Med Ed) FRCP FBPhS	Consultant Physician, University Hospitals Birmingham NHS Foundation Trust and Honorary Professor in Clinical Pharmacology and Medical Education, University of Birmingham
<b>Lay Member</b>	<b>Ms Susan Bradford</b> <sup>1</sup>	
<b>Lay Member</b>	<b>Mrs Julia Cons</b>	
<b>Lay Member</b>	<b>Mr David Crundwell</b> <sup>2</sup>	
<b>Member</b>	<b>Professor Paul I Dargan</b> MB BS FRCP Edin FACMT FRCP ERT FAACT FEAPCCT FBPhS MAE	Consultant Physician and Professor of Clinical Toxicology, Guy's and St Thomas' NHS Foundation Trust, London Professor of Clinical Toxicology, King's College London
<b>Member</b>	<b>Professor David Dockrell</b> MB BCh MD FRCPI FRCP (Glas) FACP	Professor of Infection Medicine, University of Edinburgh
<b>Member</b>	<b>Dr Jamie Fraser</b> BSc (Hons) MBChB MRCPGP	GP Partner, Southside Surgery, Inverness
<b>Member</b>	<b>Professor David Hunt</b> MB BChir FRCP PhD	Consultant Neurologist, NHS Lothian Professor of Neuroinflammatory Medicine, University of Edinburgh

<sup>1</sup> Stepped down 07/05/2023

<sup>2</sup> Appointed 12/06/2023

<b>Member</b>	<b>Professor David Moore</b> MBChB MD MSc DTM&H	Professor of Infectious Diseases and Tropical Medicine, London School of Hygiene and Tropical Medicine and Consultant in Infectious Diseases and Tropical Medicine, Hospital for Tropical Diseases, University College London Hospital
<b>Member</b>	<b>Dr Gerri Mortimore</b> PhD; MSc Advanced Practice; PgCert (IPPE); BA(Hons) Health Studies; iLM. RGN; NMP; FHEA	Associate Professor in Advanced Clinical Practice; NICE Nurse Expert Advisor
<b>Member</b>	<b>Professor Sandosh Padmanabhan</b> MBBS MD PhD FRCP(Glasg) FRCP(Edin) FBPhS FBIHS	Professor of Cardiovascular Genomics and Therapeutics, University of Glasgow
<b>Member</b>	<b>Professor Poulam Patel</b> PhD, MBBS, FRCP	Professor of Clinical Oncology, University of Nottingham
<b>Member</b>	<b>Professor Yvonne Perrie</b> BSc Hons MRPharmS FAPS FSB PhD	Chair in Drug Delivery, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow. Scotland
<b>Member</b>	<b>Professor Rui Providencia</b> MD PhD	Institute of Health Informatics Research, University College London. Consultant Cardiologist & Cardiac Electrophysiologist, Barts Health NHS Trust
<b>Member</b>	<b>Dr Vanessa Raymont</b> MBChB MSc MRCPsych	Senior Clinical Researcher, University of Oxford and Honorary Consultant Psychiatrist, Oxford Health NHS Foundation Trust
<b>Member</b>	<b>Professor Marc Turner</b> MB ChB PhD MBA FRCP FRCPATH FRSE	Professor of Cellular Therapy; Director Scottish National Blood Transfusion Service (SNBTS)
<b>Member</b>	<b>Professor Heather M Wallace</b> PhD FRCPATH FRSC FRSB FBTS FBPhS ERT	Professor Emerita of Biochemical Pharmacology and Toxicology, University of Aberdeen
<b>Member</b>	<b>Professor Christopher Weir</b> BSc (Hons) PhD MSc FRSS C.Stat	Personal Chair in Medical Statistics and Clinical Trials, Usher Institute, University of Edinburgh
<b>Member</b>	<b>Professor Anthony Williams</b> BSc MSc MRCP, FRCPATH, PhD	Professor of Translational Medicine and Honorary Consultant in Clinical Immunology and Allergy, University of Southampton and University Hospital Southampton NHS Trust
<b>Member</b>	<b>Dr Martin Wilson</b> MB ChB, MPhil (Glasgow), FRCP(Edin)	Consultant Physician in Care of the Elderly, Raigmore Hospital, Inverness

## CHM Invited Experts and Observers

Post (month)	Name and title	Affiliations (if applicable)
Invited expert (Feb)	<b>Dr Gillian M Hawksworth</b> MBE PhD FFRPS FRPharmS (Hon) DSc	Academic Community Pharmacist, Visiting Fellow at the University of Huddersfield & Past President of the RPSGB
Invited expert (Mar)	<b>Professor David Goldblatt</b> MB ChB FRCPCH FRCP PhD	Professor of Vaccinology and Immunology, Consultant in Paediatric Immunology, NIHR Senior Investigator, Great Ormond Street Hospital & University College London
Invited expert (Mar)	<b>Dr Robin Thorpe</b> BSc PhD FRCPATH	Retired, Head, Division of Biotherapeutics, National Institute for Biological Standards and Control (NIBSC) & Member of the Clinical Trials, Biologicals & Vaccines Expert Advisory Group (CTBVEAG)
Invited expert (Apr)	<b>Dr Gillian M Hawksworth</b> MBE PhD FFRPS FRPharmS (Hon) DSc	Academic Community Pharmacist, Visiting Fellow at the University of Huddersfield & Past President of the RPSGB
Invited expert (Apr)	<b>Professor Fergus Caskey</b>	Professor of renal medicine
Invited expert (May)	<b>Dr Gillian M Hawksworth</b> MBE PhD FFRPS FRPharmS (Hon) DSc	Academic Community Pharmacist, Visiting Fellow at the University of Huddersfield & Past President of the RPSGB
Invited expert (May)	<b>Mr Tony Jamieson</b> FRPharmS	Patient Safety Specialist & Clinical Improvement Lead. Medicines Safety Improvement Programme NHS England
Invited expert (Jun)	<b>Dr Mahalekshmi Desikan</b>	Clinical Fellow, UCL
Invited expert (Jun)	<b>Professor Francesco Muntoni</b> MD FRCPCH FMedSci	Director of the Dubowitz Neuromuscular Centre, Great Ormond Street Hospital
Invited expert (Jul)	<b>Professor Philip Hannaford</b> MBChB, MD, FRCGP, FFPH, FFSRH, FRSE	Emeritus Professor of Primary Care, University of Aberdeen
Invited expert (Jul)	<b>Dr Jane Ravenscroft</b>	Consultant Dermatologist at Nottingham University Hospital and Honorary Assistant Professor at the Centre for Evidence Based Dermatology, Nottingham
Invited expert (Jul)	<b>Professor Angela Thomas</b> OBE, MB BS (Hons), PhD, FRCPEdin, FRCPATH	University of Edinburgh and was Chair of the Isotretinoin EWG in 2022
Invited expert (Sep)	<b>Dr Kenneth Hodson</b> MD MBChB MRCP(UK) MRCOG	Head of UK Teratology Information Service UK Teratology Information Service

<b>Invited expert (Oct)</b>	<b>Professor Sara J Brown</b> BSc MBChB MD PhD FRCP	Professor of Dermatology, Honorary Consultant Dermatologist, Centre for Genomic and Experimental Medicine (CGEM) Institute of Genetics and Cancer (IGC), The University of Edinburgh
<b>Invited expert (Oct)</b>	<b>Professor Celia Moss</b> OBE BA(Hons) MB BS MA MRCP DM FRCP MRCPCH	Consultant Dermatologist, Birmingham Women's and Children's NHS FT, Honorary Professor of Paediatric Dermatology, University of Birmingham
<b>Invited expert (Oct)</b>	<b>Professor Sobha Sivaprasad</b> MBBS MS DM FRCS FRCOphth	Consultant Ophthalmologist, Moorfield's Eye Hospital
<b>Invited expert (Oct)</b>	<b>Professor John Wild</b> PhD DSc	Head of School, Professor of Clinical Vision Sciences, School of Optometry and Vision Sciences, College of Biomedical and Life Sciences, Cardiff University
<b>Invited expert (Oct)</b>	<b>Dr Barry Miller</b> MB ChB FRCA FFPMRCA	Consultant in Pain Medicine and Anaesthesia, Bolton NHS Foundation Trust. Board Member of the Faculty of Pain Medicine
<b>Invited expert (Nov)</b>	<b>Professor David Rees</b>	Paediatric Hematologist, King's College London & King's College Hospital
<b>Invited expert (Nov)</b>	<b>Professor James Rowe</b>	Professor of Cognitive Neurology, University of Cambridge
<b>Observers (July)</b>	<b>Dr Jolita Pancerė</b>	Clinical Pharmacologist from Lithuania, Internship in Clinical Pharmacology in Edinburgh
<b>Observers</b>	Officials from National Institute for Health and Care Excellence (NICE) have observed the following meetings: <ul style="list-style-type: none"> <li>• Feb, Mar, Apr, May, Jun, Jul, Sept, Nov</li> </ul>	
<b>Observers</b>	Official from Medicines (Regulation, Safety and Data) Policy Team, Medicines Division, Scottish Government has observed the following meeting: <ul style="list-style-type: none"> <li>• May</li> </ul>	
<b>Observers</b>	Official from Medicines Division, Northern Ireland Government has observed the following meeting: <ul style="list-style-type: none"> <li>• May</li> </ul>	
<b>Observers</b>	Official from Chief Pharmaceutical Officer, Scottish Government has observed the following meeting: <ul style="list-style-type: none"> <li>• May</li> </ul>	

## Membership of the Cardiovascular, Diabetes, Renal, Respiratory & Allergy Expert Advisory Group (CDRRA EAG)

Post	Name and title	Affiliations (if applicable)
Chair	<b>Professor Amanda Adler</b> MD PhD FRCP	Professor of Diabetic Medicine and Health Policy, University of Oxford
Member	<b>Dr Amine Boualem</b> MD MRCP PGDip(Diabetes) AHEA	GP Partner, East Barnwell Health Centre, Cambridge
Member	<b>Professor Mark Evans</b> Bsc MB BS MD FRCP	Professor of Diabetic Medicine, University of Cambridge and Consultant Physician, Cambridge University Hospitals
Member	<b>Associate Professor William G. Herrington</b> MA(Cantab) MBBS(London) MD(Cantab) FRCP(London)	Professor of Trials and Epidemiology of Kidney Disease. Medical Research Council-Population Health Research Unit at the University of Oxford; Honorary Consultant Nephrologist, Oxford Kidney Unit
Member	<b>Dr Patrick Holmes</b> MB BS MSc MRCP	GP Partner St. George's Medical Practice, Darlington
Member	<b>Dr Wajid Hussain</b> BSc (Hons) MB ChB (Hons) MSc FRCP	Consultant Cardiologist, Royal Brompton and Harefield Hospitals, Part of Guys and St Thomas' NHS Foundation Trust
Member	<b>Professor Sandosh Padmanabhan</b> MBBS MD PhD FRCP(Glasg) FRCP(Edin) FBPhS FBIHS	Professor of Cardiovascular Genomics and Therapeutics, University of Glasgow
Member	<b>Professor Patrick Mark</b> MB CHB (Hons) PhD FRCP (Glasg)	Professor of Nephrology & Honorary Consultant Nephrologist, University of Glasgow and Glasgow Renal and Transplant Unit, Queen Elizabeth University Hospital, Glasgow
Member	<b>Professor Theresa McDonagh</b> BSc (Hons), MB ChB (Hons), MD (Distinction), FRCP, FESC, FHFA	Consultant Cardiologist, King's College Hospital, London & Professor of Heart Failure King's College, London
Member	<b>Dr Shuaib Nasser</b> MA MBBS MD FRCP	Consultant Allergist and Respiratory Physician, Head of Allergy Cambridge University Hospital NHS Foundation Trust, Cambridge
Member	<b>Professor Anita K Simonds</b> MD FRCP FERS	Professor Emeritus of Respiratory and Sleep Medicine, National Heart and Lung Institute, Imperial College, London & Honorary Consultant Respiratory and Sleep Physician, Royal Brompton & Harefield Hospital, Sydney Street, London
Member	<b>Professor Michael Steiner</b> MB BS BSc MD FRCP	Professor in Respiratory Medicine and Honorary Consultant, Dept of Respiratory Science, University of Leicester

<b>Member</b>	<b>Professor Sarah Wild</b> MB BChir MSc PhD FRCPE FFPH	Professor of Epidemiology, Honorary Consultant in Public Health, Usher Institute, University of Edinburgh
---------------	--	--

## Membership of the Chemistry, Pharmacy and Standards Expert Advisory Group (CPSEAG)

Post	Name and title	Affiliations (if applicable)
<b>Chair</b>	<b>Professor Yvonne Perrie</b> BSc Hons MRPharmS FAPS FSB PhD	Chair in Drug Delivery, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow. Scotland
<b>Vice Chair</b>	<b>Dr Majella Lane</b> BSc PhD	Senior Lecturer in Pharmaceutics, UCL School of Pharmacy
<b>Lay Member</b>	<b>Mrs Ruth Paulin</b> BPharm MRPharmS	
<b>Member</b>	<b>Professor Hannah Batchelor</b> BSc PhD	Professor of Pharmaceutics and Biopharmaceutics, Strathclyde Institute of Pharmaceutical and Biomedical Sciences, University of Strathclyde
<b>Member</b>	<b>Dr Federico Brucoli</b> <sup>3</sup> Pharm. D. PhD CChem MRSC mGPhC FHEA	Senior Lecturer in Medicinal Chemistry, Leicester School of Pharmacy, De Montfort University, Leicester
<b>Member</b>	<b>Professor Barbara R Conway</b> BSc (Pharm) PhD FRPharmS CMgr FCMl	Head of Pharmacy and Professor of Pharmaceutics, University of Huddersfield, Huddersfield
<b>Member</b>	<b>Professor Ben Forbes</b> BPharm PhD	Professor of Pharmaceutics, Institute of Pharmaceutical Science, Kings College London
<b>Member</b>	<b>Professor Nikoletta Fotaki</b> <sup>4</sup> MSc, PhD, FAAPS	Professor of Biopharmaceutics, Department of Life Sciences, Centre for Therapeutic Innovation (CTI), University of Bath
<b>Member</b>	<b>Mr Robert Lowe</b> <sup>5</sup> BPharm FRPharmS	Practising Hospital Pharmacist, Specialist Pharmacy Services - East of England

<sup>3</sup> Appointed 26/03/2023

<sup>4</sup> Appointed 26/03/2023

<sup>5</sup> Appointed 26/03/2023

<b>Member</b>	<b>Professor Luigi (Gino) Martini</b> <sup>6</sup> BSc (Hons), PhD, MBA, FRPharmS, FRSC	Chief Executive Precision Health Technology Accelerator (PHTA), University of Birmingham Honorary Professor in Pharmacy, University of Birmingham
<b>Member</b>	<b>Professor Afzal R Mohammed</b> BPharm PhD	Professor of Pharmaceutics, Aston Pharmacy School, Aston University
<b>Member</b>	<b>Professor Darragh Murnane</b> PhD BSc (Pharm) PhD MRPharmS	Professor of Pharmaceutics and Associate Dean (Enterprise), University of Hertfordshire
<b>Member</b>	<b>Professor Michael D Threadgill</b> <sup>7</sup> PGCE MA PhD DSc FRSC CChem	Professor Emeritus in Medicinal Chemistry, Department of Life Sciences, University of Bath; Visiting Professor, Department of Life Sciences, Aberystwyth University
<b>Member</b>	<b>Professor Susannah E Walsh</b> PhD BSc MBA	Head of School, Professor of Pharmaceutical Microbiology, Pharmacy and Life Sciences, Robert Gordon University
<b>Member</b>	<b>Mr Hadar Zaman</b> MPharm, MFRPSII, IPresc, FHEA	Associate Professor in Pharmacy Practice and Head of School for Pharmacy and Medical Sciences, University of Bradford, Consultant Mental Health Pharmacist at Alternative Futures Group, Associated Non-Executive Director Barnsley Hospital.

---

<sup>6</sup> Appointed 26/03/2023

<sup>7</sup> End of Appointment 13/11/2023



## Membership of the Clinical Trials, Biologicals & Vaccines Expert Advisory Group (CTBVEAG)

Post	Name and title	Affiliations (if applicable)
Chair	<b>Professor Marc Turner</b> MB ChB PhD MBA FRCP FRCPATH FRSE	Professor of Cellular Therapy; Director Scottish National Blood Transfusion Service (SNBTS)
Lay Member	<b>Dr Kirstie Shearman</b> LLB MA PhD	Policy Manager, Health Research Authority
Member	<b>Professor Farzin Farzaneh</b> DPhil FRCPATH FRSB	Professor of Molecular Medicine, King's College London. Honorary Consultant in Specialist Medicine, King's College Hospital NHS Trust
Member	<b>Professor Chris Goldring</b> BSc PhD PGCert FBPhS	Professor of Pharmacology, Department of Pharmacology and Therapeutics, The University of Liverpool.
Member	<b>Professor Andrew Pollard</b> PhD FRCPCH FMedSci	Chair of the Joint Committee on Vaccination and Immunisation; Professor of Paediatric Infection and Immunity, University of Oxford
Member	<b>Dr Robin Thorpe</b> PhD FRCPATH	Retired, Head, Division of Biotherapeutics, National Institute for Biological Standards and Control (NIBSC)
Member	<b>Professor Christina Yap</b> MSci PhD Cstat	Professor of Clinical Trials Biostatistics, Team Leader in Early Phase and Adaptive Trials Team, ICR-Clinical Trials and Statistics Unit, The Institute of Cancer Research

## Membership of the Gastroenterology, Rheumatology, Immunology & Dermatology Expert Advisory Group (GRIDEAG)

Post	Name and title	Affiliations
Chair	<b>Professor Anthony Williams</b> BSc MSc MRCP FRCPath PhD	Professor of Translational Medicine and Honorary Consultant in Clinical Immunology and Allergy, University of Southampton and University Hospital Southampton NHS Trust
Lay Member	<b>Mr David Chandler</b> <sup>8</sup>	Chief Executive, Psoriasis and Psoriatic Arthritis Alliance, Hertfordshire
Member	<b>Professor Michael Ardern-Jones</b> <sup>9</sup> BSc MBBS DPhil FRCP	Associate Professor, University of Southampton and Consultant Dermatologist
Member	<b>Professor Anjan Dhar</b> DM, MD (Medicine), FRCPE, AGAF, Cert. Med. Ed, FHEA	Professor of Medicine (Teesside University), Consultant Gastroenterologist, Clinical Lead for UGI Cancers, County Durham & Darlington NHS Foundation Trust
Member	<b>Dr Shahida Din</b> BMSc, MBChB, PhD, FRCP (Edin)	Consultant Gastroenterologist & NHS Research Scotland Clinician, NHS Lothian; Honorary Senior Clinical Lecturer, University of Edinburgh
Member	<b>Professor Celia Moss</b> OBE BA(Hons) MB BS MA MRCP DM FRCP MRCPCH	Honorary Consultant Dermatologist, Birmingham Women's and Children's NHS FT; Honorary Professor of Paediatric Dermatology, University of Birmingham
Member	<b>Professor Stuart Ralston</b> MB ChB MD FRCP FMedSci FRSE FFPM (Hon)	Professor of Rheumatology, University of Edinburgh
Member	<b>Dr Ravishankar Sargur</b> MD, FRCPath, FRCP, MBA	Consultant Clinical Immunologist and Clinical Lead for Laboratory Immunology, Northern General Hospital, Sheffield
Member	<b>Professor Nidhi Sofat</b> PhD MBBS FRCP PGCert FHEA	Professor of Rheumatology, St Georges University London

<sup>8</sup> End of Appointment 16/10/2023

<sup>9</sup> Reappointed 17/09/2023

## Membership of the Infection Expert Advisory Group (IEAG)

Post	Name and title	Affiliations (if applicable)
Chair	<b>Professor David Dockrell</b> MB BCh MD FRCPI FRCP (Glas) FACP	Professor of Infection Medicine, University of Edinburgh
Lay Member	<b>Mrs Stella O'Brien</b> <sup>10</sup> MA (Hons)	
Lay Member	<b>Ms Hilary A Shenton</b> <sup>11</sup> CPFA	Retired Secretary to the School of Medicine, University of Sheffield
Member	<b>Professor Brian Angus</b> <sup>12</sup> BSc, MBChB, MA (Oxon), DTM&H, FRCP, FFTM	Professor in Infectious Diseases, University of Oxford
Member	<b>Dr Michael Brown</b> BA BM BCh FRCP PhD DTM&H	Consultant Physician, Infectious Diseases & Acute Medicine, & Clinical Director, Division of Infection, University College London Hospitals NHS Foundation Trust & Honorary Associate Professor, Clinical Research Sept, London School of Hygiene & Tropical Medicine
Member	<b>Professor Geraint Rhys Davies</b> BM DTM&H PhD FRCP	Professor of Infection Pharmacology, University of Liverpool, Honorary Consultant in Infectious Diseases, Liverpool University Hospitals Foundation Trust
Member	<b>Dr Andrew Freedman</b> <sup>13</sup> M.A, M.B, B. Chir, M.D, FRCP (Lond.), FRCP (Edin.)	Reader in Infectious Diseases, Cardiff University School of Medicine/ Hon. Consultant Physician, University Hospital of Wales
Member	<b>Professor Richard J C Gilson</b> MD FRCP	Professor of Sexual Health & HIV Medicine, Director of the UCL Centre for Clinical Research in Infection & Sexual Health & Deputy Director of the UCL Institute for Global Health
Member	<b>Dr Louis Grandjean</b> MBBS BSc MSc PhD MRCPCH	Associate Professor Paediatric Infectious Diseases Great Ormond Street Hospital and University College London

<sup>10</sup> Appointed 30/06/2023

<sup>11</sup> End of Appointment 23/03/2023

<sup>12</sup> Appointed 22/12/2023

<sup>13</sup> Reappointed 11/12/2023

<b>Member</b>	<b>Dr Susan Hopkins</b> <sup>14</sup> BA MB BCh BAO (Hons) FRCPI FCRP	Consultant in Infectious Diseases & Microbiology, Royal Free London NHS Foundation Trust, Healthcare Epidemiologist, Public Health England, Honorary Senior Lecturer, University College London
<b>Member</b>	<b>Dr Lim S Jones</b> MBBCh, PhD, FRCPATH.	Consultant Microbiologist, Public Health Wales Microbiology, Cardiff; Clinical Lead Specialist Antimicrobial Chemotherapy Unit, Cardiff; Chair of the All Wales Medical Microbiology Development & Standardisation Group
<b>Member</b>	<b>Dr Matthias Schmid</b> MD FRCP DTMH	Consultant Physician, Head of Department of Infection & Tropical Medicine, Director of Elective Studies Newcastle University, Royal Victoria Infirmary, Newcastle upon Tyne

---

<sup>14</sup> End of Appointment 23/03/2023

## Membership of the Medicines for Women's Health Expert Advisory Group (MWHEAG)

Post	Name and title	Affiliations
Chair	<b>Professor Philip Hannaford</b> MBChB MD FRCGP FFPH FFSRH FRSE	Emeritus Professor of Primary Care, University of Aberdeen
Vice Chair	<b>Dr Diana Wellesley</b> FRCP	Honorary Consultant and Honorary Senior Lecturer in Clinical Genetics, Wessex Clinical Genetics Service, Princess Anne Hospital Southampton
Lay Member	<b>Dr Caitlin Dean</b> RGN MSc PhD	Chair Trustee, Pregnancy Sickness Support
Lay Member	<b>Ms Linda Pepper</b> BA MA (Education)	Independent Consultant: patient and public involvement in healthcare
Member	<b>Dr Amparo Alvarez-Llobell</b> <sup>15</sup>	GP at Higherland Surgery GPwSI in Women's Health Speciality Dr in GUM
Member	<b>Dr Kenneth Hodson</b> MD MBChB MRCP(UK) MRCOG	Head of UK Teratology Information Service UK Teratology Information Service
Member	<b>Dr Asha Kasliwal</b> <sup>16</sup> FRCOG FFRSH FRCGP (Hon) FFPH (Hon)	Consultant in Community Gynaecology and Reproductive Health, Manchester University NHS Foundation Trust Hathersage Centre
Member	<b>Dr Jonathan Lord</b> MD, FRCOG, FHEA	Consultant obstetrician and gynaecologist, Royal Cornwall Hospitals NHS Trust and medical director, MSI Reproductive Choices UK
Member	<b>Dr Lucy MacKillop</b> BM BCh MA(Oxon.) FRCP FRCOG Ad Eundem	Consultant Obstetric Physician and Honorary Senior Clinical Lecturer, Oxford University Hospitals NHS Foundation Trust, Oxford
Member	<b>Dr Louise Massey</b> <sup>17</sup> MBChB FFSRH FFPH	Consultant in Sexual and Reproductive Health Aneurin Bevan University Health Board
Member	<b>Dr Julia Prague</b> MBBS PhD MRCP(UK) BSc	Consultant in Endocrinology, Diabetes, and General Internal Medicine, Royal Devon and Exeter NHS Foundation Trust, and Honorary Senior Clinical Lecturer, College of Medicine and Health, University of Exeter

<sup>15</sup> End of Appointment 10/03/2023

<sup>16</sup> Appointed 27/01/2023

<sup>17</sup> Appointed 27/01/2023

<b>Member</b>	<b>Professor Stuart Ralston</b> MB ChB MD FRCP FMedSci FRSE FFPM (Hon)	Professor of Rheumatology, University of Edinburgh, Western General Hospital, Edinburgh
<b>Member</b>	<b>Mr Ertan Saridogan</b> <sup>18</sup> PhD MRCOG	Consultant in Gynaecology, Reproductive Medicine and Minimal Access Surgery, University College London Hospitals (UCLH) Elizabeth Garrett Anderson Wing
<b>Member</b>	<b>Professor Laurie Tomlinson</b> MBBS MSc PhD	NIHR research Professor, Faculty of Epidemiology and Population Health London School of Hygiene & Tropical Medicine

---

<sup>18</sup> End of Appointment 10/03/2023

## Membership of the Neurology, Pain & Psychiatry Expert Advisory Group (NPPEAG)

Post	Name and title	Affiliations
Chair	<b>Professor David Hunt</b> MB BChir FRCP PhD	Consultant Neurologist, NHS Lothian Professor of Neuroinflammatory Medicine, University of Edinburgh
Member	<b>Dr Lisa Brownell</b> BSc(Hons) MBChB PGCertMedEd FHEA FRCPsych	Associate Medical Director, Birmingham and Solihull Mental Health NHS Foundation Trust Chair of Area Prescribing Committee, Birmingham, Sandwell, Solihull and Environs
Member	<b>Professor Naomi Fineberg</b> BA Hons MB BS MA MRCPsych	Consultant in General Psychiatry, Hertfordshire Partnership University NHS Foundation Trust
Member	<b>Dr Barry Mark Miller</b> MB ChB FRCA FFPMRCA	Consultant in Pain Medicine and Anaesthesia, Bolton NHS Foundation Trust. Board Member of the Faculty of Pain Medicine
Member	<b>Professor David G C Owens</b> MD (Hons) FRCP FRCPsych	Professor of Clinical Psychiatry, Edinburgh University
Member	<b>Dr Waqar Rashid</b> <sup>19</sup> MBBS BSc MRCP(UK) PhD	Consultant and Honorary Clinical Senior Lecturer in Neurology, Brighton and Sussex University Hospitals NHS Trust, member of the Multiple Sclerosis Society
Member	<b>Professor Andrew Rice</b> MB BS, MD, FRCP FRCA, FFPMRCA	Professor of Pain Research, Imperial College London, United Kingdom Honorary Consultant in Pain Medicine, Chelsea and Westminster Hospital, London, England
Member	<b>Dr Fergus Rugg-Gunn</b> MB BS MRCP PhD	Consultant Neurologist, National Hospital for Neurology and Neurosurgery, Queen Square, London
Member	<b>Dr Aditya Sharma</b> MBBS MD MRCPsych PhD	Clinical Senior Lecturer and Honorary Consultant in Child and Adolescent Psychiatry at Newcastle University and Cumbria, Northumberland Tyne and Wear NHS Foundation Trust
Member	<b>Dr Hoo Kee Tsang</b> BSc(Hons) MB BCh FRCA FFPMRCA	Consultant in Pain Medicine and Anaesthesia, Clinical Director of Pain Services, Liverpool University Hospitals NHS Foundation Trust, member of the Royal College of Anaesthetists and the Faculty of Pain Medicine training and assessment committees

<sup>19</sup> Reappointed 12/12/2023

## Membership of the Oncology & Haematology Expert Advisory Group (OHEAG)

Post	Name and title	Affiliations
Chair	<b>Professor Poulam M Patel</b> PhD MBBS FRCP	Professor of Clinical Oncology, University of Nottingham
Member	<b>Professor Janet E Brown</b> FRCP MD MSc BMedSci MBBS	Academic Unit of Clinical Oncology, Department of Oncology and Metabolism, Weston Park Hospital, University of Sheffield
Member	<b>Dr Hugo Ford</b> <sup>20</sup> MA MB BChir MD FRCP	Director of Cancer Services, Cambridge University Hospitals Foundation Trust
Member	<b>Dr Anjum Khan</b> PhD MBChB FRCPath MRCP	Consultant Haematologist, Leeds Teaching Hospitals NHS Trust
Member	<b>Dr Rebecca Kristeleit</b> BSc MBChB PhD FRCP FRSB	Consultant Medical Oncologist, Guy's and St Thomas' NHS Foundation Trust
Member	<b>Professor Siow Ming Lee</b> PhD FRCP	Professor of Medical Oncology, Consultant Medical Oncologist, University College London Hospital
Member	<b>Professor James Spicer</b> FRCP PhD	Professor of Experimental Cancer Medicine, King's College London, Consultant in Medical Oncology, Guy's & St Thomas' NHS Foundation Trust
Member	<b>Dr Ben Uttenthal</b> MA MB BS PhD MRCP FRCPath	Consultant Haematologist, Cambridge University Hospitals

---

<sup>20</sup> Stepped down 06/09/2023



## Membership of the Paediatric Medicines Expert Advisory Group (PMEAG)

Post	Name and title	Affiliations
Chair	<b>Professor Steven Cunningham</b> MBChB PhD FRCPCH	Professor of Paediatric Respiratory Medicine, University of Edinburgh and Honorary Consultant, Royal Hospital for Children and Young People, NHS Lothian, Edinburgh
Lay Member	<b>Dr Jacqueline McMurtrie</b> BSc (Hons), MSc, PhD	
Lay Member	<b>Mrs Rhian Thomas-Turner</b> LLM, PG Dip Legal Practice	Research and Development Lead, Noah's Ark Children's Hospital for Wales, Cardiff and Vale University Health Board
Member	<b>Mrs Catrin Barker</b>	Pharmacist, NHS Professionals
Member	<b>Dr Benjamin Blaise</b> <sup>21</sup> MD-PhD	Consultant Paediatric Anaesthetist, Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust Honorary Senior Lecturer, Centre for the Developing Brain, King's College London
Member	<b>Dr Simon B Drysdale</b> BSc (Hons) MBBS FRCPCH PhD PgDip PID	Consultant in Paediatric Infectious Diseases and Immunology, St George's University Hospital NHS Foundation Trust Honorary Senior Lecturer, St George's, University of London
Member	<b>Dr Martin William English</b> <sup>22</sup> BMSc, MBChB, MD, FRCP(Glas), FRCPCH	Consultant Paediatric Oncologist, Birmingham Women's and Children's Hospital NHS Foundation Trust
Member	<b>Dr Daniel Hawcutt</b> BSc (Hons), MB ChB (Hons), MD, MRCPCH	Senior Lecturer Paediatric Clinical Pharmacology, Women's and Children's Health, Institute of Translational Medicine, University of Liverpool
Member	<b>Dr Kathryn Johnson</b> MBChB FRCPCH	Consultant Neonatologist & Research Lead Yorkshire & Humber CRN Children's Specialty Lead Clinical Lead, National Congenital Anomaly and Rare Disease Registration Service, NHSD, Leeds General Infirmary
Member	<b>Dr Caroline Jones</b> MB ChB FRCPCH MD	Consultant Paediatric Nephrologist, Alder Hey Children's NHS Foundation Trust

<sup>21</sup> Resigned 30/04/2023

<sup>22</sup> Appointed 27/01/2023

<b>Member</b>	<b>Dr Ashley Liew</b> <sup>23</sup> MBChB, MRCPsych, MSc	Consultant Paediatric Neuropsychiatrist, Evelina London Children's Hospital and South London & Maudsley NHS Foundation Trust. Honorary Senior Research Fellow, University of Warwick
<b>Member</b>	<b>Dr Daniel E Lumsden</b> <sup>24</sup> MB/BChir MA Cantab MSc PhD FRCPCH	Consultant Paediatric Neurologist, Evelina London Children's Hospital Adjunct Clinical Senior Lecturer, Department of Perinatal Imaging, King's College London
<b>Member</b>	<b>Dr Rubin Minhas</b> MB ChB MBA	GP Principal
<b>Member</b>	<b>Dr Clare Pain</b> BMBS, MSc, MRPCH	Consultant Paediatric Rheumatologist, Clinical Lead for Rheumatology Honorary Clinical Lecturer, University of Liverpool Co-Chair of NIHR CRN: children/Versus Arthritis Paediatric Rheumatology Clinical Studies Group Associate Director, UK Experimental Arthritis Treatment Centre for Children (Behcet's and scleroderma workstreams)
<b>Member</b>	<b>Dr Guido Piele</b> PhD MD	Consultant Congenital Cardiologist Congenital Hear Unit, Bristol Heart Institute
<b>Member</b>	<b>Professor Shirley Price</b> <sup>25</sup> MSc, PhD, FBTS, FRSB, ERT, FHEA ,FRSC, MBPharmacolSoc	Emerita Professor of Toxicology, University of Surrey Visiting Professor of Toxicology, University of Hertfordshire Honorary Professor of Toxicology, UKHSA
<b>Member</b>	<b>Mrs Julia Taylor</b> <sup>26</sup> MSc BSc	Paediatric Advanced Nurse Practitioner, High Dependency Unit, Alder Hey Children's NHS Foundation Trust.
<b>Member</b>	<b>Dr William John Watkins</b> BSc PhD	Senior Statistician/Lecturer, College of Biomedical & Life Sciences, Cardiff University
<b>Member</b>	<b>Dr Morris Zwi</b> <sup>27</sup> MBBCh, FRCPsych	Consultant Child & Adolescent Psychiatrist, Whittington Health, Child & Adolescent Mental Health Services

<sup>23</sup> Appointed 01/05/2023

<sup>24</sup> Appointed 27/01/2023

<sup>25</sup> Appointed 27/01/2023

<sup>26</sup> Appointed 27/01/2023

<sup>27</sup> End of appointment 20/02/2023

## Membership of the Pharmacovigilance Expert Advisory Group (PEAG)

Post	Name and title	Affiliations (if applicable)
Chair	<b>Professor Jamie Coleman</b> MD MA (Med Ed) FRCP FBPhS	Consultant Physician, University Hospitals Birmingham NHS Foundation Trust and Honorary Professor in Clinical Pharmacology and Medical Education, University of Birmingham
Vice Chair	<b>Dr Daniel Hawcutt</b> BSc (Hons) MB ChB (Hons) MD, MRCPCH	Senior Lecturer in Paediatric Clinical Pharmacology, Women's and Children's Health, Institute of Translational Medicine, University of Liverpool
Lay Member	<b>Ms Susan Hunneyball</b> BSc (Hons)	
Lay Member	<b>Mrs Madeleine Wang</b> <sup>28</sup>	
Member	<b>Mrs Alana Adams</b> BPharm (Hons) MSc IP MRPharmS	Principal Pharmacist Medicines Information, advice and Safety, University of Cardiff
Member	<b>Dr Fraz Arif Mir</b> MA FRCP	Consultant Physician, Cambridge University Hospitals NHS Foundation Trust
Member	<b>Professor Darren Ashcroft</b> BPharm MSc PhD FRPharmS	Professor of Pharmacoepidemiology, Head, Drug Usage and Pharmacy Practice Group, University of Manchester
Member	<b>Professor Ann Daly</b> BA PhD FBPhS	Professor of Pharmacogenetics, Faculty of Medical Sciences, Newcastle University
Member	<b>Professor Ian J Douglas</b> <sup>29</sup> BSc MSc PhD	Professor of Pharmacoepidemiology, London School of Hygiene & Tropical Medicine
Member	<b>Professor Richard FitzGerald</b> MD MBChB PhD FRC	CRF Director, NIHR Royal Liverpool and Broadgreen CRF
Member	<b>Dr Mark Glover</b> <sup>30</sup> BA MA MB BChir MRCP PhD	Associate Professor and Honorary Consultant Physician, Clinical Pharmacology and General Medicine, University of Nottingham

<sup>28</sup> Reappointed 22/01/2023

<sup>29</sup> End of Appointment 14/09/2023

<sup>30</sup> End of Appointment 23/01/2023

<b>Member</b>	<b>Dr Patricia McGettigan</b> BSc (Pharm) MD FRCPI FRACP SFHEA FBPhS	Reader in Clinical Pharmacology and Medical Education, Queen Mary University of London, Consultant Physician, Barts Health NHS Trust
<b>Member</b>	<b>Dr Karen Miller</b> <sup>31</sup> BSc MBBS DRCOG DCH DFFP FRCGP	GP Partner, Adelaide Medical Centre, London
<b>Member</b>	<b>Professor Rupert Payne</b> MB ChB PhD MRCGP FRCPE FBPhS FHEA	Professor of Primary Care & Clinical Pharmacology University of Exeter
<b>Member</b>	<b>Professor Reecha Sofat</b> MBBS, FRCP, PhD	Breckenridge Chair of Clinical Pharmacology and Therapeutics, University of Liverpool.
<b>Member</b>	<b>Dr Ruben Thanacoody</b> <sup>32</sup> MD FRCP FRCP (Edin)	Consultant Physician, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust Honorary Clinical Senior Lecturer in Clinical Pharmacology, Newcastle University Honorary Consultant Clinical Toxicologist, UK Health Security Agency Director National Poisons Information Service (Newcastle unit)

---

<sup>31</sup> End of Appointment 14/09/2023

<sup>32</sup> End of Appointment 14/09/2023

## Membership of the CHM's Cancer Vaccines Expert Working Group

Post	Name and title	Affiliations
Chair	<b>Professor Sir Munir Pirmohamed</b> MB ChB (Hons) PhD FRCP FRCP (Edin) FBPhS, FFPM (Hon) FMedSci	David Weatherall Chair of Medicine, University of Liverpool, NHS Chair of Pharmacogenetics, Director of the Wolfson Centre for Personalised Medicine, Director of the Centre for Drug Safety Science
Lay Member	<b>Mrs Julia Cons</b>	
Member	<b>Dr Robert Andrews</b>	Senior Lecturer FHEA Data Hub at Heath, Cardiff
Member	<b>Dr Colin Brown</b> PhD FRCPPath	Consultant Clinical Scientist -Head of H&I Laboratory Colindale NHS Blood and Transplant
Member	<b>Professor Robert Brown</b> BSc PhD	Professor of Translational Oncology, Department of Surgery & Cancer, Imperial College London
Member	<b>Dr Peter Buckle</b> FRSPH, FIEHF, FIEA, C.ErgHF	Principal Research Fellow, NIHR London In Vitro Diagnostics Co-operative Department of Surgery and Cancer, Faculty of Medicine, Imperial College London
Member	<b>Professor Tom Clutton-Brock</b> MBE MB ChB FRCP FRCA	Director, Medical Devices Testing and Evaluation Centre, Clinical Director, NIHR Trauma Management MedTech Cooperative, Chair, NICE Interventional Procedures Advisory Committee, Associate Medical Director, University Hospitals Birmingham NHS Foundation Trust, Professor of Anaesthesia & Intensive Care Medicine, University of Birmingham, New Chair of the interim Devices Committee
Member	<b>Professor Jamie Coleman</b> MD MA (Med Ed) FRCP FBPhS	Consultant Physician, University Hospitals Birmingham NHS Foundation Trust and Honorary Professor in Clinical Pharmacology and Medical Education, University of Birmingham
Member	<b>Professor Ann Daly</b> BA PhD FBPhS	Professor of Pharmacogenetics, Faculty of Medical Sciences, Newcastle University
Member	<b>Professor Jon Deeks</b> PhD CStat	Professor of Biostatistics Public Health, Epidemiology and Biostatistics, Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham

<b>Member</b>	<b>Dr Brendan Fish</b> BSc PhD	Director of Biologics & RNA Centre of Excellence
<b>Member</b>	<b>Professor Eric Lim</b> MB ChB MD MSc FRCS(C-Th)	Consultant Thoracic Surgeon, Royal Brompton Hospital, Professor of Thoracic Surgery, Imperial College London
<b>Member</b>	<b>Mr Robert Lowe</b> BPharm FRPharmS	Practising Hospital Pharmacist, Specialist Pharmacy Services - East of England
<b>Member</b>	<b>Dr David Millrine</b> PhD	Translational Immunology Team lead, CRUK Cancer Biomarker Centre, University of Manchester
<b>Member</b>	<b>Professor Christian Ottensmeier</b> MD, PhD, FRCP	Professor of Molecular and Clinical Cancer Medicine, University of Liverpool
<b>Member</b>	<b>Professor Poulam Patel</b> PhD, MBBS, FRCP	Professor of Clinical Oncology, University of Nottingham
<b>Member</b>	<b>Professor Yvonne Perrie</b> BSc PhD	Professor in Drug Delivery within the Strathclyde Institute of Pharmacy and Biomedical Sciences
<b>Member</b>	<b>Professor Shirley Price</b> MSc, PhD, FBTS, FRSB, ERT, FHEA, FRSC, MBPharmacolSoc	Emerita Professor of Toxicology, University of Surrey Visiting Professor of Toxicology, University of Hertfordshire Honorary Professor of Toxicology, UKHSA
<b>Member</b>	<b>Professor Jacqui Shaw</b> BSc PhD	Group Leader and Professor of Translational Cancer Genetics, Leicester University
<b>Member</b>	<b>Professor James Spicer</b> FRCP, PhD	Professor of Experimental Cancer Medicine, King's College London; Consultant in Medical Oncology, Guy's & St Thomas' NHS Foundation Trust
<b>Member</b>	<b>Professor Nigel Stallard</b> BA MSc PhD	Professor of Medical Statistics Director Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry
<b>Member</b>	<b>Professor Kevin M G Taylor</b> BPharm PhD FRPharmS	Emeritus Professor of Clinical Pharmaceutics, UCL School of Pharmacy, London
<b>Member</b>	<b>Dr Robin Thorpe</b> BSc PhD FRCPPath	Retired, Head, Division of Biotherapeutics, National Institute for Biological Standards and Control (NIBSC) & Member of the Clinical Trials, Biologics & Vaccines Expert Advisory Group (CTBVEAG)
<b>Member</b>	<b>Dr David Turner</b> PhD FRCPPath	H&I Laboratory, Scottish National Blood Transfusion Service, Royal Infirmary of Edinburgh
<b>Member</b>	<b>Professor Marc Turner</b> MBBS PhD MBA FRCP FRCPPath	Professor of Cellular Therapy; Medical Director Scottish National Blood Transfusion Service

<b>Member</b>	<b>Professor Christopher Weir</b> BSc MSc PhD FRSS Cstat	Professor of Medical Statistics & Clinical Trials, Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh & Member of Commission on Human Medicines (CHM)
<b>Member</b>	<b>Professor Anthony Williams</b> BSc MSc MRCP, FRCPath, PhD	Professor of Translational Medicine and Honorary Consultant in Clinical Immunology and Allergy, University of Southampton and University Hospital Southampton NHS Trust
<b>Member</b>	<b>Professor Christina Yap</b> MSci PhD C. Stat	Professor of Clinical Trial Biostatistics, Team Leader in Early Phase and Adaptive Trials Team, ICR-Clinical Trials and Statistics Unit, The Institute of Cancer Research [Cancer UK/ UK CI]
<b>Member</b>	<b>Professor Christopher Yau</b> MA MEng DPhil	Professor of Artificial Intelligence, Nuffield Department of Women's & Reproductive Health, University of Oxford and Health Data Research UK
<b>Member</b>	<b>Professor Ly-Mee Yu</b> BSc MSc DPhil	Professor of Clinical Trials and Biostatistics, Deputy Director Academic of Primary Care Clinical Trials Unit, Nuffield Department of Primary Care Health Sciences, University of Oxford

## Membership of the CHM's Isotretinoin Implementation Expert Working Group

Post	Name and title	Affiliations (if applicable)
Chair	Dr Jane Ravenscroft	Consultant Dermatologist at Nottingham University Hospital and Honorary Assistant Professor at the Centre for Evidence Based Dermatology, Nottingham
Lay Member	Ms Sara Payne	
Member	Professor Steven Cunningham MBChB PhD FRCPCH	Professor of Paediatric Respiratory Medicine, University of Edinburgh and Honorary Consultant, Royal Hospital for Children and Young People, University of Edinburgh, Edinburgh
Member	Dr Hannah DeJong BA DPhil ClinPsyD	Senior Clinical Psychologist, Oxford University Hospitals NHS Foundation Trust
Member	Dr Karen Gibbon	Consultant Dermatologist
Member	Dr Holly Hardy	Associate Dean (GP) Bristol, North Somerset & South Gloucestershire Clinical Lead Bristol, North Somerset & South Gloucestershire Training Hub GP Horfield Health Centre
Member	Dr Tess McPherson	Consultant Paediatric Dermatologist
Member	Professor David G C Owens	Professor of Clinical Psychiatry, Edinburgh University
Member	Professor Angela Thomas OBE MB BS PhD FRCPE FRCPath	University of Edinburgh
Member	Member1	Dermatologist
Member	Member2	Clinician in Dermatology
Member	Member3	Consultant Dermatologist
Member	Member4	Child And Adolescent Psychiatrist lead, Clinical Director
Member	Member5	Dermatology specialist nurse
Member	Member6	Consultant Child & Adolescent Psychiatrist & Clinical Director
Member	Member7	Consultant Paediatrician



## Membership of the Real World Data Ad Hoc Group

Post	Name and title	Affiliations
Chair	<b>Professor Deborah Ashby OBE</b> FMedSci	Interim Dean of the Faculty of Medicine, Imperial College London
Member	<b>Professor Janet Darbyshire CBE</b> MB ChB FMedSci FRCP FFPH FRSS (Hon)	Emeritus Professor of Epidemiology, University College London
Member	<b>Dr Colin Forfar</b> BSc (Hons) MBChB PhD MD MA FRCP FRCP (Edin)	Retired Consultant Physician and Cardiologist, John Radcliffe Hospital, Oxford
Member	<b>Dr Peter Hall</b> MB ChB MRCP PhD	Reader in Cancer Informatics and Health Economics, University of Edinburgh
Member	<b>Dr Daniel Hawcutt</b> BSc (Hons) MB ChB (Hons) MD MRCPCH	Senior Lecturer in Paediatric Clinical Pharmacology, Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Member of Pharmacovigilance Expert Advisory Group (PEAG) and Member of Paediatric Medicines Expert Advisory Group (PMEAG)
Member	<b>Professor Sarah Meredith</b>	Professor of Clinical Trials, MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, Invited Expert of the Commission on Human Medicines (CHM)
Member	<b>Professor Sir Munir Pirmohamed</b> MB ChB (Hons) PhD FRCP FRCP (Edin) FBPhS, FFPM (Hon) FMedSci	David Weatherall Chair of Medicine, University of Liverpool, NHS Chair of Pharmacogenetics, Director of the Wolfson Centre for Personalised Medicine, Director of the Centre for Drug Safety Science, Chair of the Commission on Human Medicines (CHM)
Member	<b>Professor Christopher Weir</b> BSc (Hons) PhD MSc FRSS C.Stat	Personal Chair in Medical Statistics and Clinical Trials, Usher Institute, University of Edinburgh

## Membership of the Topiramate Implementation Expert Working Group

Post	Name and title	Affiliations
Chair	<b>Professor David Hunt</b> MB BChir FRCP PhD	Consultant Neurologist, NHS Lothian Professor of Neuroinflammatory Medicine, University of Edinburgh
Member	<b>Dr Jamie Fraser</b> BSc MB ChB MRCP	GP Partner, Southside Surgery, Inverness
Member	<b>Dr Fergus Rugg-Gunn</b> MB BS MRCP PhD	Consultant Neurologist, National Hospital for Neurology and Neurosurgery, Queen Square, London

## Membership of the Valproate Epigenetics Expert Working Group

Post	Name and title	Affiliations
Chair	<b>Professor Anthony Williams</b> BSc MSc MRCP, FRCPath, PhD	Professor of Translational Medicine and Honorary Consultant in Clinical Immunology and Allergy, University of Southampton and University Hospital Southampton NHS Trust
Lay Member	<b>Ms Julia Cons</b>	
Member	<b>Professor Amanda Drake</b>	Retired, Professor, Centre for Cardiovascular Science The Queen's Medical Research Institute University of Edinburgh
Member	<b>Professor Timothy Gant</b>	Head of the Toxicology Department, Radiation Effects Department Radiation, Chemical & Environmental Hazards
Member	<b>Professor David Hunt</b> MB BChir FRCP PhD	Consultant Neurologist, NHS Lothian Professor of Neuroinflammatory Medicine, University of Edinburgh
Member	<b>Professor Rod Mitchell</b>	Professor of Developmental Endocrinology, Centre for Reproductive Health, University of Edinburgh Honorary Consultant Paediatric Endocrinologist, Royal Hospital for Children and Young People, Edinburgh
Member	<b>Professor Shirley Price</b> MSc, PhD, FBTS, FRSB, ERT, FHEA, FRSC, MBPharmacolSoc	Emerita Professor of Toxicology, University of Surrey Visiting Professor of Toxicology, University of Hertfordshire Honorary Professor of Toxicology, UKHSA
Member	<b>Professor Heather M Wallace</b> PhD FRCPath FRSC FRSB FBTS FBPhS ERT	Professor Emeritus of Biochemical Pharmacology and Toxicology, University of Aberdeen
Member	<b>Member8</b>	Professor at the Human Genetics Unit
Member	<b>Member9</b>	Professor of Translational Oncology
Member	<b>Member10</b>	Professor of Developmental Epigenetics

## Membership of the CHM's Valproate Implementation Working Group

Post	Name and title	Affiliations
Chair	<b>Professor David Hunt</b> MB BChir FRCP PhD	Consultant Neurologist, NHS Lothian Professor of Neuroinflammatory Medicine, University of Edinburgh
Member	<b>Professor Helen Cross</b>	The Prince of Wales's Chair of Childhood Epilepsy, Director UCL Great Ormond Street Institute of Child Health
Member	<b>Professor Naomi Fineberg</b>	Consultant Adult Psychiatrist and Professor of Psychiatry, University of Hertfordshire
Member	<b>Dr Daniel Hawcutt</b> BSc (Hons) MB ChB (Hons) MD MRCPCH	Reader Paediatric Clinical Pharmacology Women's & Children's Health, University of Liverpool. Consultant Paediatric Clinical Pharmacologist (Alder Hey Children's Hospital). Director of Research Alder Hey Children's Hospital and Director of NIHR Alder Hey Clinical Research Facility (CRF)
Member	<b>Mr Tony Jamieson</b> FRPharmS	Patient Safety Specialist & Clinical Improvement Lead. Medicines Safety Improvement Programme, NHS England
Member	<b>Professor Anthony Marson</b>	Professor of Neurology, University of Liverpool, The Walton Centre NHS Foundation Trust, NIHR Senior Investigator
Member	<b>Dr Tejal Mitchell</b>	Consultant Neurologist Subspecialty Lead for Epilepsy, Northwest Anglia NHS Foundation Trust and Cambridge University Hospitals NHS Foundation Trust
Member	<b>Ms Kim Morley</b>	Advanced Clinical Nurse/Midwife Practitioner in Epilepsy, Hampshire Hospitals NHS Foundation
Member	<b>Prof Finbar O'Callaghan</b>	Professor of Paediatric Neuroscience, Developmental Neurosciences Dept UCL GOS Institute of Child Health
Member	<b>Professor David G C Owens</b>	Professor of Clinical Psychiatry, Edinburgh University
Member	<b>Dr Vanessa Raymont</b>	Senior Clinical Researcher and Honorary Consultant Psychiatrist, Department of Psychiatry, University of Oxford
Member	<b>Dr Martin Wilson</b>	Consultant Physician in Care of the Elderly, Raigmore Hospital, Inverness
Member	<b>Member11</b>	Consultant Neurologist
Member	<b>Member12</b>	Consultant Neurologist

## Membership of the COVID-19 Vaccine Benefit Risk Expert Working Group

Post	Name and title	Affiliations
Chair	<b>Professor Sir Munir Pirmohamed</b> MB ChB (Hons) PhD FRCP FRCP (Edin) FBPhS, FFPM (Hon) FMedSci	David Weatherall Chair of Medicine, University of Liverpool, NHS Chair of Pharmacogenetics, Director of the Wolfson Centre for Personalised Medicine, Director of the Centre for Drug Safety Science
Lay Member	<b>Ms Susan Hunneyball</b> BSc(Hons)	Member of the Pharmacovigilance Expert Advisory Group (PEAG) and Advisory Board on the Registration of Homeopathic Products (ABRHP)
Lay Member	<b>Mrs Madeleine Wang</b> BA (Hons)	Patient Advocate
Member	<b>Professor Judith Breuer</b> MD FRCPATH FmedSci	Professor of Virology, University College London (UCL), Division of Infection and Immunity, London
Member	<b>Professor Gordon Dougan</b> FRS	Department of Medicine, Cambridge Infectious Diseases, University of Cambridge
Member	<b>Mr V'lain G Fenton-May</b> BPharm MIPharm FRPharmS	Pharmaceutical Microbiologist
Member	<b>Professor Neil French</b> MB ChB FRCP PhD	Head Department of Clinical Infection Microbiology and Immunology, Chair of Infectious Diseases & Global Health, Hon Consultant Infectious Diseases, Royal Liverpool & Broadgreen University Hospitals Trust
Member	<b>Professor David Goldblatt</b> MB ChB FRCPCH FRCP PhD	Professor of Vaccinology and Immunology, Consultant in Paediatric Immunology, NIHR Senior Investigator, Great Ormond Street Hospital & University College London
Member	<b>Professor Kimme Hyrich</b> MD PhD FRCPC	Honorary Consultant in Rheumatology, Centre for Musculoskeletal Research, Faculty of Biology Medicine and Health, University of Manchester and Kellgren Centre for Rheumatology, Manchester University NHS Foundation Trust
Member	<b>Sir Michael Jacobs</b> MA PhD MB BS FRCP FRCP Edin DTM&H	Consultant in Infectious Diseases, Royal Free London NHS Foundation Trust; Hon. Senior Lecturer, University College London and Liverpool School of Tropical Medicine

<b>Member</b>	<b>Professor Helen J Lachmann</b> MA MB BChir MD FRCP FRCPATH	Professor of Medicine & Honorary Consultant Nephrologist Clinical Director UCL Division of Medicine & Clinical Lead for National Amyloidosis Centre, University College London & Royal Free Hospital London NHS Foundation Trust
<b>Member</b>	<b>Professor Paul J Lehner</b> PhD FRCP FMedSci FRS	Professor of Immunology and Medicine, Wellcome Trust Principal Research Fellow Honorary Consultant Infectious Diseases, Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre Cambridge Biomedical Campus
<b>Member</b>	<b>Mr Robert Lowe</b> BPharm FRPharmS	Practising Hospital Pharmacist, Specialist Pharmacy Services - East of England
<b>Member</b>	<b>Dr Siraj Misbah</b> MBBS (Hons) MSc FRCP FRCPATH	Consultant Clinical Immunologist, Lead for Clinical Immunology, Oxford University Hospitals
<b>Member</b>	<b>Professor Yvonne Perrie</b> BSc Hons MRPharmS FAPS FSB PhD	Chair in Drug Delivery, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, Scotland
<b>Member</b>	<b>Professor Shirley Price</b> MSc, PhD, FBTS, FRSB, ERT, FHEA, FRSC, MBPharmacolSoc	Emerita Professor of Toxicology, University of Surrey Visiting Professor of Toxicology, University of Hertfordshire Honorary Professor of Toxicology, UKHSA
<b>Member</b>	<b>Dr Andrew Riordan</b> MD FRCPCH DTM&H	Consultant in Paediatric Infectious Diseases and Immunology, Honorary Clinical Lecturer, University of Liverpool, Alder Hey Children's NHS Foundation Trust, Liverpool
<b>Member</b>	<b>Professor Chris Robertson</b> PhD MSc BSc	Professor of Public Health Epidemiology, University of Strathclyde
<b>Member</b>	<b>Professor Tom Solomon</b> FRCP PhD	Chair, Neurological Science, Director, NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Associate Pro-Vice-Chancellor for Infrastructure and Environment, Faculty of Health and Life Sciences, University of Liverpool & Honorary Consultant Neurologist, Walton Centre NHS Foundation Trust
<b>Member</b>	<b>Professor Kevin M G Taylor</b> BPharm PhD FRPharmS	Emeritus Professor of Clinical Pharmaceutics, UCL School of Pharmacy, London

<b>Member</b>	<b>Dr Robin Thorpe</b> BSc PhD FRCPATH	Retired, Head, Division of Biotherapeutics, National Institute for Biological Standards and Control (NIBSC) & Member of the Clinical Trials, Biologicals & Vaccines Expert Advisory Group (CTBVEAG)
<b>Member</b>	<b>Professor Marc Turner</b> MB ChB PhD MBA FRCP FRCPATH FRSE	Professor of Cellular Therapy; Director Scottish National Blood Transfusion Service (SNBTS)
<b>Member</b>	<b>Professor Susannah E Walsh</b> PhD BSc MBA	Head of School, Professor of Pharmaceutical Microbiology, Pharmacy and Life Sciences, Robert Gordon University
<b>Member</b>	<b>Professor Christopher Weir</b> BSc MSc PhD FRSS Cstat	Professor of Medical Statistics & Clinical Trials, Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh & Member of Commission on Human Medicines (CHM)

## Membership of the COVID-19 Therapeutic Expert Working Group

Post	Name and title	Affiliations (if applicable)
Chair	<b>Professor Jonathan S Friedland</b> MA PhD FRCP FRCPE FRCPI FESCMID FMedSci	Deputy Principal, St. George's, University of London
Lay Member	<b>Ms Susan Bradford</b>	
Member	<b>Professor Kenneth Baillie</b> BSc(Hons) MBChB PhD FRCA FRCP FFICM	Professor of Experimental Medicine, Roslin Institute, University of Edinburgh
Member	<b>Professor David Dockrell</b> MB BCh MD FRCPI FRCP (Glas) FACP	Professor of Infection Medicine, University of Edinburgh
Member	<b>Professor Richard J C Gilson</b> MD FRCP	Professor of Sexual Health & HIV Medicine, Director of the UCL Centre for Clinical Research in Infection & Sexual Health & Deputy Director of the UCL Institute for Global Health
Member	<b>Sir Michael Jacobs</b> MA PhD MB BS FRCP FRCP Edin DTM&H	Consultant in Infectious Diseases, Royal Free London NHS Foundation Trust; Hon. Senior Lecturer, University College London and Liverpool School of Tropical Medicine
Member	<b>Professor Nigel Klein</b> BSc MBBS MRCP PhD FRCPCH	Consultant, Great Ormond Street Hospital for Children NHS Trust; Professor of Infectious Diseases and Microbiology, Institute of Child Health, UCL
Member	<b>Dr Siraj Misbah</b> MBBS (Hons) MSc FRCP FRCPPath	Consultant Clinical Immunologist, Lead for Clinical Immunology, Oxford University Hospitals
Member	<b>Professor Deenan Pillay</b>	Professor of Virology, UCL Pro-Vice-Provost International
Member	<b>Professor Sir Munir Pirmohamed</b> MB ChB (Hons) PhD FRCP FRCP (Edin) FBPhS, FFPM (Hon) FMedSci	David Weatherall Chair of Medicine, University of Liverpool, NHS Chair of Pharmacogenetics, Director of the Wolfson Centre for Personalised Medicine, Director of the Centre for Drug Safety Science
Member	<b>Professor Shirley Price</b> MSc, PhD, FBTS, FRSB, ERT, FHEA, FRSC, MBPharmacolSoc	Emerita Professor of Toxicology, University of Surrey Visiting Professor of Toxicology, University of Hertfordshire Honorary Professor of Toxicology, UKHSA
Observers	Official from Therapeutics Taskforce, Department of Health & Social Care	



<b>Observers</b>	Officials from Public Health England
<b>Observers</b>	Officials from Scientific Affairs, National Institute for Health and Care Excellence (NICE)
<b>Observers</b>	Officials from Science, Policy and Research Programme, NICE
<b>Observers</b>	Officials from NHS England & NHS Improvement



## ANNEX A - DECLARATION OF INTERESTS

Commission on Human Medicines, Commission's Expert Advisory Groups, Expert Working Groups and ad hoc groups members have declared current personal and non-personal interests in the pharmaceutical industry as follows:

Member	Committee(s)	Interest Type	Company / Organisation / Sponsor	Nature of Interest	Current	Additional Information
Aditya Sharma	NPPEAG	Personal	NIL	N/A	N/A	
Aditya Sharma	NPPEAG	Non-Personal	Lundbeck	Unrestricted medical educational grant towards a study	Yes	
Afzal Mohammed	CPSEAG	Personal	Aston Particle Technologies	Shares, Consultancy	Yes	
Afzal Mohammed	CPSEAG	Non-Personal	Catalent Pharma	Research Grant	Yes	
Afzal Mohammed	CPSEAG	Non-Personal	Colorcon Ltd	Research Grant	No	
Afzal Mohammed	CPSEAG	Non-Personal	MaxBiotech Ltd	Research Grant	Yes	
Afzal Mohammed	CPSEAG	Non-Personal	Proveca Ltd	Research Grant	Yes	

Afzal Mohammed	CPSEAG	Non-Personal	Quest Healthcare	Research Grant	Yes
Alana Adams	PEAG	Personal	Pfizer	Consultancy	No
Alana Adams	PEAG	Non-Personal	NIL	N/A	N/A
Aldert Piersma	Valproate Epigenetics EWG	Personal	NIL	N/A	N/A
Aldert Piersma	Valproate Epigenetics EWG	Non-Personal	NIL	N/A	N/A
Amanda Adler	CHM, CDRRA EAG	Personal	NIL	N/A	N/A
Amanda Adler	CHM, CDRRA EAG	Non-Personal	NovoNordisk	Grant	Yes
Amanda Adler	CHM, CDRRA EAG	Non-Personal	Lilly	Investigator on global cardiovascular safety trial - no personal financial gain.	Yes
Amanda Drake	Valproate Epigenetics EWG	Personal	NIL	N/A	N/A
Amanda Drake	Valproate Epigenetics EWG	Non-Personal	NIL	N/A	N/A

Amine Boualem	CDRRA EAG	Personal	NIL	N/A	N/A
Amine Boualem	CDRRA EAG	Non-Personal	NIL	N/A	N/A
Amparo Alvarez-Llobell	MWHEAG				
Andrew Freedman	IEAG	Personal	NIL	N/A	N/A
Andrew Freedman	IEAG	Non-Personal	Janssen UK	Local PI for ENSEMBLE- 2 Trial	No
Andrew Freedman	IEAG	Non-Personal	Moderna	Local PI for mRNA-1018-P101 Odyssey Study	Yes
Andrew Pollard	CTBVEAG	Personal	Shionogi	Consultancy	No
Andrew Pollard	CTBVEAG	Non-Personal	Seqirus, Sanofi, GSK, Moderna, MSD	Unrestricted grant for 3-day educational course paid to Oxford University	Yes
Andrew Pollard	CTBVEAG	Non-Personal	Astra Zeneca	Partnership between Oxford University and AZ for development of a Covid19 vaccine.	Yes
Andrew Pollard	CTBVEAG	Non-Personal	Moderna	In-Kind support of synthetic RNA to Oxford University	Yes

Andrew Pollard	CTBVEAG	Non-Personal	Serum Institute of India	Grant to Oxford University	Yes
Andrew Pollard	CTBVEAG	Additional			Non-commercial: Grants from Wellcome and Bill & Melinda Gates Foundation on typhoid vaccines (Tybar-CV, Bharat Biotech, 2013-current); from MRC on paratyphoid vaccine (U. Maryland; from 2018-); Grant from the Gavi on pneumococcal vaccines in Nepal (2013-current).
Andrew Pollard	CTBVEAG	Additional			European Commission (EC): EC IMI grants (EBOVAC), on Ebola vaccine (Janssen; 2015-current); (PERISCOPE) on pertussis vaccines (2016-current); (RESCEU and PROMISE) on RSV biomarkers (2016-Current). EC H2020 grant (PERFORM/DIAMONDS) on fever in children and pneumonia (2016-current); EC grant (Innovac4) to develop a CDiff challenge model (2021-current);

Andrew Pollard	CTBVEAG	Additional	Innovate UK			Grants from Innovate UK to develop plague, Q fever vaccines (2016-current) and Chikungunya/Mayaro Virus vaccines (2023- current).
Andrew Pollard	CTBVEAG	Additional	CEPI			Grants from CEPI on COVID19 vaccines (2021-current)
Andrew Pollard	CTBVEAG	Additional	Meningitis Res Found'n			Grant from Meningitis Res Found'n on a booster of Bexsero in teens (2018-current), and MRC on novel meningococcal vaccine; Grant from Bill & Melinda Gates Found'n on evaluating infant schedules (2019 – current)
Andrew Rice	NPPEAG	Personal	PharmNovo, Astra Zeneca, Confo Therapeutic & CombiGene	Fee remunerated consultancy work from Imperial College Consultants	Yes	
Andrew Rice	NPPEAG	Personal	Imperial College London	Salary	Yes	
Andrew Rice	NPPEAG	Non-Personal	UKRI (Medical Research Council)	Research grants and contracts to support research at Imperial College	Yes	

Versus Arthritis

Alan & Sheila  
Diamond  
Charitable Trust

Ministry of  
Defence

Dr Jennie Gwynn  
Bequest

Andrew Riordan	COVID-19 VBREWG	Personal	NIL	N/A	N/A
Andrew Riordan	COVID-19 VBREWG	Non- Personal	GSK	Local PI for Zanamivir Effectiveness study (OXON)	Yes
Andrew Hattersley	RWD EWG	Personal	NIL	N/A	N/A
Andrew Hattersley	RWD EWG	Non- Personal	NIL	N/A	N/A
Anthony Marson	Valproate Implementation EWG	Personal	NIL	N/A	N/A
Anthony Marson	Valproate Implementation EWG	Non- Personal	Sanofi	Fees paid to University for an online lecture	No



Anthony Marson	Valproate Implementation EWG	Non-Personal	Jazz	Fees paid to University for attending advisory board	No
Anthony Marson	Valproate Implementation EWG	Non-Personal	Jazz	Fees paid to University for lecture to Jazz team	No
Angela Thomas	Isotretinoin Implementation EWG	Personal	CTG Catapult	Non-Executive Director: remunerated and travel and accommodation costs	Yes
Angela Thomas	Isotretinoin Implementation EWG	Personal	Canna Capital plc	Medical adviser; not remunerated as company closed and no advice therefore given	No
Angela Thomas	Isotretinoin Implementation EWG	Non-Personal	NIL	N/A	N/A
Anita Simonds	CDRRA EAG	Personal	NIL	N/A	N/A
Anita Simonds	CDRRA EAG	Non-Personal	NIL	N/A	N/A
Anjan Dhar	GRIDEAG	Personal	Takeda UK	Consultancy and Advisory Role, speaker fees	Yes
Anjan Dhar	GRIDEAG	Personal	Janssen UK	Consultancy, advisory and speaker fees	Yes

Anjan Dhar	GRIDEAG	Personal	Dr Falk Pharma UK	Consultancy, advisory and speaker fees	Yes
Anjan Dhar	GRIDEAG	Personal	Galapagos	Advisory role, speaker fees	Yes
Anjan Dhar	GRIDEAG	Personal	Abbvie UK	Speaker Fees and Chair	Yes
Anjan Dhar	GRIDEAG	Personal	BMS	Speaker fees	Yes
Anjan Dhar	GRIDEAG	Personal	Health Beacon	Speaker fees	Yes
Anjan Dhar	GRIDEAG	Personal	Tillotts UK	Speaker Fees and Chair	Yes
Anjan Dhar	GRIDEAG	Conference /Scientific Meetings	Janssen UK	ECCO 2023: Full registration, travel and accommodation	No
Anjan Dhar	GRIDEAG	Conference /Scientific Meetings	Tillotts Pharma UK	United European Gastroenterology Week: Full registration, travel and accommodation	No
Anjan Dhar	GRIDEAG	Non-Personal	NIL	N/A	N/A
Anjum Khan	OHEAG	Personal	Jazz	Consultancy	No
Anjum Khan	OHEAG	Personal	AbbVie	Fee-Paid Work	No
Anjum Khan	OHEAG	Conference /Scientific Meetings	American Society of Haematology	Conference attendance and flights, accommodation	No

Anjum Khan	OHEAG	Conference /Scientific Meetings	European Haematology Association	Conference attendance and flights, accommodation	No
Anjum Khan	OHEAG	Conference /Scientific Meetings	European Society for Blood & Marrow Transplantation	Conference attendance and flights, accommodation	No
Anjum Khan	OHEAG	Non-Personal	NIL	N/A	N/A
Ann Daly	PEAG, Cancer Vaccines EWG	Personal	NIL	N/A	N/A
Ann Daly	PEAG, Cancer Vaccines EWG	Non-Personal	NIL	N/A	N/A
Anthony Williams	CHM, GRID EAG, Cancer Vaccines EWG, Valproate Implementation EWG	Personal	NIL	N/A	N/A
Anthony Williams	CHM, GRID EAG, Cancer Vaccines EWG, Valproate Implementation EWG	Non-Personal	NIL	N/A	N/A
Asha Kasliwal	MWHEAG	Personal	Bayer	Received fees for lecturing	No

Asha Kasliwal	MWHEAG	Non-Personal	Federation International Obstetrics and Gynaecology (FIGO)	Contraception Committee Chair	Yes
Ashley Liew	PMEAG	Personal	NIL	N/A	N/A
Ashley Liew	PMEAG	Conference /Scientific Meetings	Flynn Pharma	ESCAP: Expenses	No
Ashley Liew	PMEAG	Non-Personal	NIL	N/A	N/A
Barbara Conway	CPSEAG	Personal	NIL	N/A	N/A
Barbara Conway	CPSEAG	Conference /Scientific Meetings	Journal of Woundcare	Wounds Week - Honorarium	No
Barbara Conway	CPSEAG	Conference /Scientific Meetings	Urgo Medical	Honorarium, Expenses and hospitality	No
Barbara Conway	CPSEAG	Non-Personal	Paxman Coolers	Research grant	No
Barry Miller	NPPEAG	Personal	NIL	N/A	N/A
Barry Miller	NPPEAG	Non-Personal	NIL	N/A	N/A

Barry Miller	NPPEAG	Additional				Elected Board Member of the Faculty of Pain Medicine (FPM) (and former Dean) Current Lead for Medicines Management at the FPM, with specific remit covering the 'Opioids Aware' website a national resource for guidance on opioid prescribing.
Benjamin Blaise	PMEAG	Personal	NIL	N/A	N/A	
Benjamin Blaise	PMEAG	Non-Personal	NIL	N/A	N/A	
Ben Forbes	CPSEAG	Personal	NIL	N/A	N/A	
Ben Forbes	CPSEAG	Non-Personal	AstraZeneca	Grant	Yes	
Ben Uttenthal	OHEAG	Personal	NIL	N/A	N/A	
Ben Uttenthal	OHEAG	Conference /Scientific Meetings	Gilead	Sponsorship to attend American Society of Haematology annual scientific meeting	No	
Ben Uttenthal	OHEAG	Non-Personal	NIL	N/A	N/A	

Brendan Fish	Cancer Vaccines EWG	Personal	GSK, Haleon	Shares	Yes
Brendan Fish	Cancer Vaccines EWG	Non-Personal	NIL	N/A	N/A
Brian Angus	IEAG	Personal	NIL	N/A	N/A
Brian Angus	IEAG	Non-Personal	NIL	N/A	N/A
Caitlin Dean	MWHEAG	Personal	NIL	N/A	N/A
Caitlin Dean	MWHEAG	Non-Personal	NIL	N/A	N/A
Caroline Jones	PMEAG	Personal	NIL	N/A	N/A
Caroline Jones	PMEAG	Non-Personal	NIL	N/A	N/A
Catrin Barker	PMEAG	Personal	NIL	N/A	N/A
Catrin Barker	PMEAG	Non-Personal	NIL	N/A	N/A
Celia Moss	GRIDEAG	Personal	NIL	N/A	N/A
Celia Moss	GRIDEAG	Non-Personal	NIL	N/A	N/A
Celia Moss	GRIDEAG	Additional			Trustee and Chair of the Medical Advisory Board for

						the National Eczema Society (charity)
Chris Goldring	CTBVEAG	Personal	NIL	N/A	N/A	
Chris Goldring	CTBVEAG	Non-Personal	Pfizer, MSD, Roche, Eli Lilly, Novartis, Janssen, Sanofi-Aventis	Grant for Innovative Medicines Initiative project	Yes	
Chris Goldring	CTBVEAG	Non-Personal	RedX Pharma	Consultancy	Yes	
Chris Goldring	CTBVEAG	Non-Personal	Merck	Grant	Yes	
Chris Goldring	CTBVEAG	Additional				On the organising committee for a scientific meeting in June 2023, a joint meeting of the International Society for the Study of Xenobiotics (ISSX) and the Drug Metabolism Discussion Group (DMDG). There are many Pharmaceutical Industry members of both of these societies. I receive no financial gain from my role on the committee, which is comprised of a mixture of

						academic and Industry scientists.
Chris Robertson	COVID-19 VBREWG	Personal	NIL	N/A	N/A	
Chris Robertson	COVID-19 VBREWG	Non- Personal	NIL	N/A	N/A	
Chris Robertson	COVID-19 VBREWG	Additional				Research Grants to Strathclyde University to carry out work on vaccine effect, uptake and safety funded by Public Health Scotland, MRC, CSO, NIHR.
Chris Robertson	COVID-19 VBREWG	Additional				Member of SPI-M and was a member of the Scottish Government Covid 19 Scientific Advisory Committee
Christian Ottensmeier	Cancer Vaccines EWG	Personal	Neuvogen	Consultancy (SAB)	Yes	
Christian Ottensmeier	Cancer Vaccines EWG	Personal	Transgene	Consultancy (presentation)	Yes	
Christian Ottensmeier	Cancer Vaccines EWG	Conference /Scientific Meeting	Scancell	ESMO: Funding for travel	No	



Christian Ottensmeier	Cancer Vaccines EWG	Non-Personal	Transgene	CI of clinical trial	Yes
Christian Ottensmeier	Cancer Vaccines EWG	Non-Personal	Scancell	CI of clinical trial	Yes
Christian Ottensmeier	Cancer Vaccines EWG	Non-Personal	BioNTech	CI of clinical trial	Yes
Christian Ottensmeier	Cancer Vaccines EWG	Non-Personal	Akamis bio	CI of clinical trial	Yes
Christian Ottensmeier	Cancer Vaccines EWG	Non-Personal	Bristol Myers Squibb	Research funding	Yes
Christian Ottensmeier	Cancer Vaccines EWG	Non-Personal	Touchlight Genetics	Development of a clinical trial	Yes
Christian Ottensmeier	Cancer Vaccines EWG	Non-Personal	Merck	Clinical trials funding	Yes
Christian Ottensmeier	Cancer Vaccines EWG	Non-Personal	Verastem	Clinical trials funding	Yes
Christian Ottensmeier	Cancer Vaccines EWG	Non-Personal	Lineage therapeutics	Trial funding (trial sponsored by CRUK)	Yes
Christina Yap	CTBVEAG, Cancer Vaccines EWG	Personal	Faron Pharmaceuticals	Independent Statistical Consultant	Yes

Christina Yap	CTBVEAG, Cancer Vaccines EWG	Personal	Duke Street	Research grant as statistical methodologist/advisor	Yes
Christina Yap	CTBVEAG, Cancer Vaccines EWG	Non- Personal	AstraZeneca	Trial grant (where I am a co- investigator)	Yes
Christina Yap	CTBVEAG, Cancer Vaccines EWG	Non- Personal	Plexxikon	Trial grant (where I am a co- investigator)	No
Christopher Weir	CHM, COVID- 19 VBREWG, RWD EWG, Cancer Vaccines EWG	Personal	NIL	N/A	N/A
Christopher Weir	CHM, COVID- 19 VBREWG, RWD EWG, Cancer Vaccines EWG	Non- Personal	AB Science	DSMB membership for three trials (in ALS, mastocytosis and progressive MS), with income to my department	Yes
Christopher Weir	CHM, COVID- 19 VBREWG, RWD EWG, Cancer Vaccines EWG	Non- Personal	Eli Lilly	Research grant to institution, on which I am co-applicant	Yes
Christopher Yau	Cancer Vaccines EWG	Personal	Singula Bio	Consultancy	Yes

Christopher Yau	Cancer Vaccines EWG	Personal	Health Data Research UK	Secondment	Yes	
Christopher Yau	Cancer Vaccines EWG	Non-Personal	Roche	Grant to Health Data Research UK to fund an Academic Summer School in Health Data Science	Yes	
Clare Pain	PMEAG	Personal	NIL	N/A	N/A	
Clare Pain	PMEAG	Non-Personal	NIL	N/A	N/A	
Clare Pain	PMEAG	Additional				Currently have industry studies open at our site with the following companies: Abbvie – in set up from Dec 2023, Amgen – UK CI for paediatric Behcet’s trial of apremilast (ongoing), Amgen – PEAPOD study of apremilast in psoriatic JIA (PI) – in closure stage, Lilly – baricitinib in several JIA studies (sub-investigator), Lilly – ixekizumab in JIA – in follow-up (sub-investigator)
Colin Brown	Cancer Vaccines EWG	Personal	NIL	N/A	N/A	

Colin Brown	Cancer Vaccines EWG	Non-Personal	NIL	N/A	N/A
Colin Forfar	RWD EWG	Personal	NIL	N/A	N/A
Colin Forfar	RWD EWG	Non-Personal	NIL	N/A	N/A
Daniel Hawcutt	PEAG, PMEAG, RWD EWG, Valproate Implementation EWG	Personal	NIL	N/A	N/A
Daniel Hawcutt	PEAG, PMEAG, RWD EWG, Valproate Implementation EWG	Non-Personal	NIL	N/A	N/A
Daniel Hawcutt	PEAG, PMEAG, RWD EWG, Valproate Implementation EWG	Additional			

I am the Director of the NIHR Alder Hey Clinical Research Facility – we have over 60 studies open at any one time, and I am a named investigator or PI on many of them. I do not get paid for my time, it is recycled into the finances of the CRF, and nothing comes to me personally. I

report any product specific COIs during a meeting where it is listed on the agenda as non-personal non-specific for the chair to consider

Daniel Lumsden	PMEAG	Personal	Taysha	Consultancy for ongoing clinical trial; Chief Investigator in the UK for this study	Yes
Daniel Lumsden	PMEAG	Non-Personal	NIL	N/A	N/A
Darragh Murnane	CPSEAG	Personal	Adare Pharmaceuticals Inc. (New Jersey, USA)	Consultancy	Yes
Darragh Murnane	CPSEAG	Personal	Fluid Pharma Ltd.	Non-personal, University Director and no personal benefit	Yes
Darragh Murnane	CPSEAG	Personal	Informix Pharma Ltd.	Personal, Founder and Director	Yes
Darragh Murnane	CPSEAG	Conference /Scientific Meetings	Bespak, Merxin Ltd.	DDL 2023: Hospitality at Company reception	No
Darragh Murnane	CPSEAG	Conference /Scientific Meetings	Innovatrix Conference Organizers	Registration and accommodation costs paid for by conference organizers.	No

Darragh Murnane	CPSEAG	Conference /Scientific Meetings	Merxin Ltd	RDD Europe 2023 - Hospitality	No
Darragh Murnane	CPSEAG	Conference /Scientific Meetings	RDD Online	RDD Europe 2023: Speakers Fees	No
Darragh Murnane	CPSEAG	Conference /Scientific Meetings	Merxin Ltd	SMI.London: registration fee	No
Darragh Murnane	CPSEAG	Conference /Scientific Meetings	Zeiss	Zeiss User Meeting - Travel expenses and accommodation	Yes
Darragh Murnane	CPSEAG	Conference /Scientific Meetings	Zeiss	Hospitality at RDD Europe 2023 conference	No
Darragh Murnane	CPSEAG	Non-Personal	Chiesi Ltd	Sponsored PhD student at University of Hertfordshire	Yes
Darragh Murnane	CPSEAG	Non-Personal	GlaxoSmithKline	In-kind support for research project and sponsored PhD studentship at University of Hertfordshire	No
Darragh Murnane	CPSEAG	Non-Personal	AstraZeneca	In-kind support for research project at University of Hertfordshire	Yes

Darragh Murnane	CPSEAG	Non-Personal	Kindeva Drug Delivery Ltd.	In-kind support for research project at University of Hertfordshire	No
Darragh Murnane	CPSEAG	Non-Personal	Philips Respironics	Sponsored PhD Studentship at University of Hertfordshire	No
Darragh Murnane	CPSEAG	Non-Personal	Philips Respironics	Loaned Equipment at University of Hertfordshire	Yes
Darragh Murnane	CPSEAG	Non-Personal	Clement Clarke International	Funded contract research at University of Hertfordshire, provision of respiratory devices for research	Yes
Darragh Murnane	CPSEAG	Non-Personal	Bespak Recipharm	Funding for collaborative research project, co-funded by Innovate UK.  Consultancy and contract research at University of Hertfordshire	Yes
Darragh Murnane	CPSEAG	Non-Personal	Bespak	Two sponsored research students at University of Hertfordshire	Yes
Darragh Murnane	CPSEAG	Non-Personal	Merxin Ltd.	Sponsored PhD Studentship at University of Hertfordshire	Yes
Darragh Murnane	CPSEAG	Non-Personal	Capitainer Ab	Sponsored PhD Studentship at University of Hertfordshire	Yes

Darren Ashcroft	PEAG, IEWG	Personal	NIL	N/A	N/A
Darren Ashcroft	PEAG, IEWG	Non-Personal	Abbvie, Amgen (was Celgene), Janssen, Eli Lilly, Novartis (Sandoz), UCB, LEO Foundation	Research grant to support the development of the Global Psoriasis Atlas	Yes
David Chandler	GRIDEAG	Personal	NIL	N/A	N/A
David Chandler	GRIDEAG	Non-Personal	NIL	N/A	N/A
David Chandler	GRIDEAG	Additional			I'm employed by a patient charity, but the charity has a policy not to receive any funding or financial support whether monetary, in kind or via a third parties from pharmaceutical companies or other commercial organisations. Any events or meetings I attend in relation to my work for the charity are funded by the charity, this includes: registration fees, travel, subsistence and accommodation. Family member also works for the



same charity, and the above, also applies.

David Chandler	GRIDEAG	Additional				Another family member works within the NHS as a diagnostic radiographer with nuclear medicine specialty, but has no personal or financial connections in the pharmaceutical industry. No other members of my immediate household have any financial interests in the pharmaceutical industry or associated organisations.
David Crundwell	CHM	Personal	NIL		N/A	N/A
David Crundwell	CHM	Non-Personal	NIL		N/A	N/A
David Crundwell	CHM	Additional				Chair of the NHS CPAG committee (Clinical Priorities Advisory Group), 3-year term ending April '26.
David Crundwell	CHM	Additional				Chair of British Psychological Society Charity unpaid Trustee, resigned March 2024

David Crundwell	CHM	Additional				Chair of Imperial Healthcare Charity, unpaid Trustee
David Dockrell	CHM, COVID-19 Therapeutic EWG, IEAG	Personal	NIL	N/A	N/A	
David Dockrell	CHM, COVID-19 Therapeutic EWG, IEAG	Non-Personal	GSK	No direct financial benefit, in kind contribution of compounds.	Yes	
David Dockrell	CHM, COVID-19 Therapeutic EWG, IEAG	Non-Personal	Adiso Therapeutics, Inc GlaxoSmithKline Pfizer Inc Chan Zuckerberg Initiative Santerus AG IPInc Intercept Pharmaceuticals inc Gene One Genentech Inc Stryker International Sanofi Pasteur MSD Limited GlaxoSmithKline UCBC UCB BioPharma Srl Novartis Pharma AG	Industry companies for whom the academic centre I am director of (Centre for Inflammation Research, University of Edinburgh) has current industry sponsorship through grants or other support to investigators. Other than GSK above not direct to me.	Yes	

Galecto Biotech  
 AB  
 Corin Ltd  
 Scottish Power  
 Astra Zeneca  
 Canon  
 Gene cell catapult

David Dockrell	CHM, COVID-19 Therapeutic EWG, IEAG	Non-Personal	Astra Zeneca	I have been an advisor on a research project and have reviewed and been included on a research publication-not yet published. Compounds involved in assays listed. No financial benefit	No
David Goldblatt	COVID-19 VBREWG	Personal	NIL	N/A	N/A
David Goldblatt	COVID-19 VBREWG	Non-Personal	NIL	N/A	N/A
David Hunt	CHM, NPP EAG, Topiramate Implementation EWG, Valproate Epigenetics EWG, Valproate Implementation EWG	Personal	NIL	N/A	N/A

David Hunt	CHM, NPP EAG, Topiramate Implementation EWG, Valproate Epigenetics EWG, Valproate Implementation EWG	Non-Personal	NIL	N/A	N/A
David Millrine	Cancer Vaccines EWG	Personal	NIL	N/A	N/A
David Millrine	Cancer Vaccines EWG	Non-Personal	NIL	N/A	N/A
David Moore	CHM	Personal	NIL	N/A	N/A
David Moore	CHM	Non-Personal	NIL	N/A	N/A
David Owens	NPPEAG, Isotretinoin Implementation EWG, Valproate Implementation EWG	Personal	NIL	N/A	N/A
David Owens	NPPEAG, Isotretinoin Implementation EWG, Valproate	Non-Personal	NIL	N/A	N/A

	Implementation EWG				
David Turner	Cancer Vaccines EWG	Personal	NIL	N/A	N/A
David Turner	Cancer Vaccines EWG	Non- Personal	NIL	N/A	N/A
Deborah Ashby	RWD EWG	Personal	NIL	N/A	N/A
Deborah Ashby	RWD EWG	Conference /Scientific Meeting	Phastar	Sally Hollis Memorial Lecture (speaker) - Expenses, Dinner to follow lecture	No
Deborah Ashby	RWD EWG	Non- Personal	NIL	N/A	N/A
Deenan Pillay	COVID-19 Therapeutic EWG	Personal	NIL	N/A	N/A
Deenan Pillay	COVID-19 Therapeutic EWG	Non- Personal	NIL	N/A	N/A
Diana Wellesley	MWHEAG	Personal	NIL	N/A	N/A
Diana Wellesley	MWHEAG	Non- Personal	NIL	N/A	N/A

Eric Lim	Cancer Vaccines EWG	Personal	AstraZeneca	Consultancy, advisory board, fee paid education, NICE expert advisor	Yes
Eric Lim	Cancer Vaccines EWG	Personal	Boehringer Ingelheim	Consultancy	Yes
Eric Lim	Cancer Vaccines EWG	Personal	Medela	Consultancy, advisory board, fee paid education	Yes
Eric Lim	Cancer Vaccines EWG	Personal	Beigene	Consultancy	Yes
Eric Lim	Cancer Vaccines EWG	Personal	Roche	Consultancy, advisory board, fee paid education	Yes
Eric Lim	Cancer Vaccines EWG	Personal	BMS	Consultancy, advisory board, fee paid education	Yes
Eric Lim	Cancer Vaccines EWG	Personal	Merck Sharp and Dohme	Advisory Board	No
Eric Lim	Cancer Vaccines EWG	Personal	Johnson and Johnson	Conference Sponsor-Grand Rounds in Thoracic Surgery	No
Eric Lim	Cancer Vaccines EWG	Personal	Medtronic	Conference Sponsor-Grand Rounds in Thoracic Surgery	Yes
Eric Lim	Cancer Vaccines EWG	Personal	Medela	Conference Sponsor-Grand Rounds in Thoracic Surgery	Yes
Eric Lim	Cancer Vaccines EWG	Non-Personal	AstraZeneca	Unrestricted grant	Yes

Eric Lim	Cancer Vaccines EWG	Non-Personal	Lilly	Unrestricted grant	Yes
Eric Lim	Cancer Vaccines EWG	Non-Personal	Bayer	Unrestricted grant	Yes
Eric Lim	Cancer Vaccines EWG	Non-Personal	Boehringer Ingelheim	Unrestricted grant	Yes
Eric Lim	Cancer Vaccines EWG	Non-Personal	Takeda	Unrestricted grant	Yes
Eric Lim	Cancer Vaccines EWG	Non-Personal	Roche	Unrestricted grant	Yes
Ertan Saridogan	MWHEAG	Personal	Hologic	Consultancy, honoraria for lectures	Yes
Ertan Saridogan	MWHEAG	Personal	Karl Storz	Honorarium for a lecture	No
Ertan Saridogan	MWHEAG	Personal	De Gruyter	Royalty on edited a book	Yes
Ertan Saridogan	MWHEAG	Conference /Scientific Meetings	Arthrex	Laparoscopic hysterectomy cadaveric course - fees	No
Ertan Saridogan	MWHEAG	Conference /Scientific Meetings	Hologic	Innovation forum - fees	No

Ertan Saridogan	MWHEAG	Non-Personal	NIL	N/A	N/A
Farzin Farzeneh	CTBVEAG	Personal	Apterna	Consultancy	Yes
Farzin Farzeneh	CTBVEAG	Personal	Autolus Therapeutics	Shares	Yes
Farzin Farzeneh	CTBVEAG	Personal	Autolus Therapeutics	Consultancy, Contract Manufacture and R & D Collaborations	No
Farzin Farzeneh	CTBVEAG	Personal	VacV Therapeutics	Consultancy	Yes
Farzin Farzeneh	CTBVEAG	Personal	Dawn Therapeutics	Shares and Consultancy	Yes
Farzin Farzeneh	CTBVEAG	Personal	GSK	Consultancy – Member of “Cell and Therapy Scientific Advisory Board	No
Farzin Farzeneh	CTBVEAG	Personal	ViroCell Biologics Ltd	Chief Scientific Officer, Co-Founder and Share Holder	Yes
Farzin Farzeneh	CTBVEAG	Non-Personal	NIL	N/A	N/A
Federico Brucoli	CPSEAG	Personal	NIL	N/A	N/A



Federico Brucoli	CPSEAG	Non-Personal	NIL	N/A	N/A
Fergus Rugg-Gunn	NPPEAG, Topiramate Implementation EWG	Personal	NIL	N/A	N/A
Fergus Rugg-Gunn	NPPEAG, Topiramate Implementation EWG	Non-Personal	NIL	N/A	N/A
Finbar O'Callaghan	Valproate Implementation EWG	Personal	NIL	N/A	N/A
Finbar O'Callaghan	Valproate Implementation EWG	Conference / Scientific Meeting	UCB Biopharma	Epilepsy Forum of Excellence: speaker honorarium	No
Finbar O'Callaghan	Valproate Implementation EWG	Non-Personal	NIL	N/A	N/A
Fraz Mir	PEAG	Personal	British National Formulary	Chair of Joint Formulary Committee and Senior Medical Advisor	Yes
Fraz Mir	PEAG	Conference /Scientific Meeting	A variety of pharma companies – AZ, Menarini	Sponsored the meeting that I co-sponsored. No money paid to me	No

Fraz Mir	PEAG	Non-Personal	NIL	N/A	N/A
Geraint Davies	IEAG	Personal	Viiv Healthcare	Research grant (co-investigator, no personal, salary or other benefits)	Yes
Geraint Davies	IEAG	Non-Personal	NIL	N/A	N/A
Geraint Davies	IEAG	Additional			

From 2011-2017 I was the academic co-ordinator of the PreDiCT-TB consortium, a public-private partnership funded by the EU Innovative Medicines Initiative and the European Federation of Pharmaceutical Industries and Associations. However, though this role involved engagement with industrial partners (GSK, Sanofi, Janssen) in pre-competitive areas of research into TB drug development, these activities were fully supported by public funding from the EU and neither myself nor my research institution received any

funding from EFPIA or from the individual industrial partners.

Geraint Davies    IEAG                    Additional

Since 2017 I have been an academic partner to the PanACEA clinical trials consortium, funded by the European and Developing Countries Clinical Trials Partnership. Though the consortium has involved contact and collaboration with pharmaceutical partners, my role is as a partner without budget supporting the clinical trials site at the College of Medicine in Blantyre, Malawi. Neither myself, the University of Liverpool nor the University of Malawi College of Medicine receive any funding from pharmaceutical collaborators as part of these activities.

Geraint Davies    IEAG                    Additional

Since 2020 I have been an academic partner to the UNITE4TB consortium, a new public-private

partnership funded by the EU Innovative Medicines Initiative and the European Federation of Pharmaceutical Industries until 2028. However, though this role involved engagement with industrial partners (GSK, Janssen, Evotech) in pre-competitive areas of research into TB drug development, these activities were fully supported by public funding from the EU and neither myself nor my research institution received any funding from EFPIA or from the individual industrial partners.

Geraint Davies    IEAG                      Additional

I have attended expert advisory meetings relating to TB drug development convened by GSK and Janssen for which I received no payment or benefit (honorarium, expenses, hospitality)

Gerri Mortimore    CHM                      Personal    NIL                      N/A                      N/A

Gerri Mortimore	CHM	Non-Personal	NIL	N/A	N/A
Gerri Mortimore	CHM	Additional			Director of Mortimore Healthcare Services Ltd, a private practice owned by immediate family member. Not paid a salary from this account.
Gordon Dougan	COVID-19 VBREWG	Personal	NIL	N/A	N/A
Gordon Dougan	COVID-19 VBREWG	Non-Personal	NIL	N/A	N/A
Guido Pieleles	PMEAG	Personal	Canon Medical Systems	Non-pharmaceutical: Consultancy (lecturing, strategy of sports cardiology imaging)	Yes
Guido Pieleles	PMEAG	Personal	Cardiac Health & Performance Ltd.	Non-pharmaceutical (clinical sports cardiology and sports medicine consulting): Director	Yes
Guido Pieleles	PMEAG	Non-Personal	NIL	N/A	N/A
Hadar Zaman	CPSEAG	Personal	NIL	N/A	N/A
Hadar Zaman	CPSEAG	Non-Personal	NIL	N/A	N/A

Hannah Batchelor	CPSEAG	Personal	NIL	N/A	N/A
Hannah Batchelor	CPSEAG	Non-Personal	UCB	Grant awarded to support a PhD student under my supervision	Yes
Hannah Batchelor	CPSEAG	Non-Personal	GSK	Grant awarded to support a PhD student under my supervision	Yes
Hannah Dejong	Isotretinoin Implementation EWG	Personal	NIL	N/A	N/A
Hannah Dejong	Isotretinoin Implementation EWG	Non-Personal	NIL	N/A	N/A
Heather Wallace	CHM, Valproate Epigenetics EWG	Personal	NIL	N/A	N/A
Heather Wallace	CHM, Valproate Epigenetics EWG	Non-Personal	NIL	N/A	N/A
Heather Wallace	CHM, Valproate Epigenetics EWG	Additional			

I am Chair of Medical Research Scotland. We fund PhD studentships, and each studentship has an external partner organisation (EPO). This

can be industry or charity. The relationship is between the student, supervisor and university. Medical Research Scotland provides funds to the University who funds the student but has no relationship with the student or the EPO.

Heather Wallace	CHM, Valproate Epigenetics EWG	Additional			
Helen Cross	Valproate Implementation EWG	Personal	NIL	N/A	N/A
Helen Cross	Valproate Implementation EWG	Non-Personal	Nutricia	Educational seminar, remuneration to department	No
Helen Cross	Valproate Implementation EWG	Non-Personal	Stoke Therapeutics	Clinical investigator in clinical trial	Yes
Helen Cross	Valproate Implementation EWG	Non-Personal	Ultragenyx	Clinical investigator in clinical trial	Yes

I am the Vice chair of the CONTAM Panel at EFSA where we provide scientific opinions in contaminants in food and feed.

Helen Cross	Valproate Implementation EWG	Non-Personal	Zogenix/UCB	Clinical investigator in clinical trial	Yes	
Helen Cross	Valproate Implementation EWG	Non-Personal	Biocodex	Educational seminar, remuneration to department	No	
Helen Cross	Valproate Implementation EWG	Additional				<p>National Childrens Epilepsy Surgery Service Clinical Advisor</p> <p>Ongoing Topic Advisor to NICE CG217 (epilepsies)</p> <p>Elected President International League Against Epilepsy 2021-2025</p> <p>Chair of Medical Advisory Board Matthews Friends, Dravet UK, and Hope for Hypothalamic Hamartoma,</p> <p>Trustee Young Epilepsy</p> <p>Non Executive Director Great Ormond Street Hospital for Children</p> <p>President Epilepsy Research Institute</p>
Helen Lachmann	COVID-19 VBREWG	Personal	Novartis	Consultancy and honoraria	No	



Helen Lachmann	COVID-19 VBREWG	Personal	SOBI	Consultancy and honoraria	No
Helen Lachmann	COVID-19 VBREWG	Personal	AstraZeneca	Consultancy	Yes
Helen Lachmann	COVID-19 VBREWG	Personal	Johnson and Johnson	Honoraria	No
Helen Lachmann	COVID-19 VBREWG	Personal	Uptodate	Editors fees	Yes
Helen Lachmann	COVID-19 VBREWG	Non-Personal	NIL	N/A	N/A
Helen Lachmann	COVID-19 VBREWG	Additional			

I am clinical lead of the national amyloidosis centre. I am not the signatory nor beneficiary on any agreements with pharma but other consultants within the unit have received industry support from Alynlam (patisiran and Vitrusiran), Pfizer (Tafamadis), intellia and Regeneron (CRISPAR-CAS9 STUDIES) and Richmond pharmaceuticals relating to agents targeting TTR amyloid and covering staff salaries and consumables.

Hilary Shenton	IEAG	Personal	NIL	N/A	N/A
Hilary Shenton	IEAG	Non-Personal	NIL	N/A	N/A
Holly Hardy	Isotretinoin Implementation EWG	Personal	NIL	N/A	N/A
Holly Hardy	Isotretinoin Implementation EWG	Non-Personal	NIL	N/A	N/A
Hoo Kee Tsang	NPP EAG	Personal	NIL	N/A	N/A
Hoo Kee Tsang	NPP EAG	Non-Personal	NIL	N/A	N/A
Hugo Ford	OHEAG	Personal	NIL	N/A	N/A
Hugo Ford	OHEAG	Non-Personal	NIL	N/A	N/A
Ian Douglas	PEAG	Personal	GlaxoSmithKline	Shares	Yes
Ian Douglas	PEAG	Non-Personal	GlaxoSmithKline	Research Grants	Yes
Ian Douglas	PEAG	Non-Personal	AstraZeneca	Research Grants	Yes

Jacqueline McMurtrie	PMEAG	Personal	NIL	N/A	N/A
Jacqueline McMurtrie	PMEAG	Non-Personal	NIL	N/A	N/A
Jacqueline McMurtrie	PMEAG	Additional	WRK Orthopedics		Director at immediate family member's private practice. Neither of us have any affiliation with any pharmaceutical or medical appliance companies.
Jacqui Shaw	Cancer Vaccines EWG	Personal	Thermo Fisher Scientific	Loan of equipment for collaborative project and development of applications on a flow cytometer	Yes
Jacqui Shaw	Cancer Vaccines EWG	Non-Personal	NIL	N/A	N/A
James Spicer	OHEAG, Cancer Vaccines EWG	Personal	Epsilon Ltd	Co-founding shareholder	Yes
James Spicer	OHEAG, Cancer Vaccines EWG	Personal	APOBEC Discovery	Non-executive director	Yes
James Spicer	OHEAG, Cancer Vaccines EWG	Personal	BMS	Assistance with attendance at international meetings	No
James Spicer	OHEAG, Cancer Vaccines EWG	Personal	MSD	Assistance with attendance at international meetings	No

James Spicer	OHEAG, Cancer Vaccines EWG	Non-Personal	Achilles	Reimbursement to my institution for recruitment to clinical trials	Yes
James Spicer	OHEAG, Cancer Vaccines EWG	Non-Personal	Gilead	Reimbursement to my institution for recruitment to clinical trials	Yes
James Spicer	OHEAG, Cancer Vaccines EWG	Non-Personal	IO Biotech	Reimbursement to my institution for recruitment to clinical trials	Yes
James Spicer	OHEAG, Cancer Vaccines EWG	Non-Personal	MSD	Reimbursement to my institution for recruitment to clinical trials	Yes
James Spicer	OHEAG, Cancer Vaccines EWG	Non-Personal	Roche	Reimbursement to my institution for recruitment to clinical trials	Yes
James Spicer	OHEAG, Cancer Vaccines EWG	Non-Personal	RS Oncology	Reimbursement to my institution for recruitment to clinical trials	Yes
James Spicer	OHEAG, Cancer Vaccines EWG	Non-Personal	Starpharma	Reimbursement to my institution for recruitment to clinical trials	Yes
James Spicer	OHEAG, Cancer Vaccines EWG	Non-Personal	APOBEC Discovery	Reimbursement to my institution for advisory role	Yes
James Spicer	OHEAG, Cancer Vaccines EWG	Non-Personal	Avacta	Reimbursement to my institution for advisory role	Yes
James Spicer	OHEAG, Cancer Vaccines EWG	Non-Personal	AstraZeneca	Reimbursement to my institution for advisory role	Yes
James Spicer	OHEAG, Cancer Vaccines EWG	Non-Personal	BMS	Reimbursement to my institution for advisory role	Yes

James Spicer	OHEAG, Cancer Vaccines EWG	Non-Personal	Roche	Reimbursement to my institution for advisory role	Yes
Jamie Coleman	CHM, PEAG, Cancer Vaccines EWG	Personal	NIL	N/A	N/A
Jamie Coleman	CHM, PEAG, Cancer Vaccines EWG	Non-Personal	NIL	N/A	N/A
Jamie Fraser	CHM, Topiramate Implementation EWG	Personal	NIL	N/A	N/A
Jamie Fraser	CHM, Topiramate Implementation EWG	Non-Personal	NIL	N/A	N/A
Jane Ravenscroft	Topiramate Implementation EWG	Personal	NIL	N/A	N/A
Jane Ravenscroft	Topiramate Implementation EWG	Non-Personal	NIL	N/A	N/A
Janet Brown	OHEAG	Personal	NIL	N/A	N/A
Janet Brown	OHEAG	Non-Personal	NIL	N/A	N/A

Janet Darbyshire	RWD EWG	Personal	NIL	N/A	N/A
Janet Darbyshire	RWD EWG	Non-Personal	NIL	N/A	N/A
Jon Deeks	Cancer Vaccines EWG	Personal	NIL	N/A	N/A
Jon Deeks	Cancer Vaccines EWG	Non-Personal	NIL	N/A	N/A
Jonathan Friedland	COVID-19 Therapeutic EWG	Personal	NIL	N/A	N/A
Jonathan Friedland	COVID-19 Therapeutic EWG	Non-Personal	Astra Zeneca	The commercial company is a sponsor / funder of research at St. George's, University of London which does not involve me (and of which I am generally unaware of the topic)	Yes
Jonathan Friedland	COVID-19 Therapeutic EWG	Non-Personal	Chiesi Limited	As above	Yes
Jonathan Friedland	COVID-19 Therapeutic EWG	Non-Personal	Fondazione PENTA ONLUS	As Above	Yes

Jonathan Friedland	COVID-19 Therapeutic EWG	Non-Personal	Gilead Sciences Ltd.	As above	Yes
Jonathan Friedland	COVID-19 Therapeutic EWG	Non-Personal	GlaxoSmithKline	As above	Yes
Jonathan Friedland	COVID-19 Therapeutic EWG	Non-Personal	Pfizer UK / Global / USA	As above	Yes
Judith Breuer	COVID-19 VBREWG	Personal	GSK	CI on a GSK sponsored study commissioned by MHRA to understand emergence of sotrovimab resistance mutations in SARS-CoV-2	No
Judith Breuer	COVID-19 VBREWG	Non-Personal	NIL	N/A	N/A
Julia Cons	CHM, Cancer Vaccines EWG, Valproate Epigenetics EWG	Personal	NIL	N/A	N/A
Julia Cons	CHM, Cancer Vaccines EWG, Valproate Epigenetics EWG	Non-Personal	NIL	N/A	N/A

Julia Cons	CHM, Cancer Vaccines EWG, Valproate Epigenetics EWG	Additional				I am Vice Chair of the Ministry of Defence Research Ethics Committee (MODREC) and I am Independent Chair of NHS England's Individual Funding Request (IFR) Panel.
Julia Cons	CHM, Cancer Vaccines EWG, Valproate Epigenetics EWG	Additional				I am Lay Board Member of the Midlands Burn Operational Delivery Network, and I am Vice Chair of the NHS England Specialised Commissioning patient and Public Voice assurance Group.
Julia Prague	MWHEAG	Personal	AstraZeneca Synairgen Sareum Holdings GSK Haleon	Immediate family member has very minor shareholding	Yes	
Julia Prague	MWHEAG	Non-Personal	NIL	N/A	N/A	
Julia Prague	MWHEAG	Additional				I am an Associate Editor of Endocrine Related Cancer



Journal (not associated with any financial remuneration)

Julia Taylor	PMEAG	Personal	NIL	N/A	N/A
Julia Taylor	PMEAG	Non-Personal	NIL	N/A	N/A
Karen Gibbon	Isotretinoin Implementation EWG	Personal	NIL	N/A	N/A
Karen Gibbon	Isotretinoin Implementation EWG	Non-Personal	NIL	N/A	N/A
Karen Miller	PEAG	Personal	NIL	N/A	N/A
Karen Miller	PEAG	Non-Personal	NIL	N/A	N/A
Kathryn Johnson	PMEAG	Personal	NIL	N/A	N/A
Kathryn Johnson	PMEAG	Non-Personal	NIL	N/A	N/A
Kenneth Baillie	COVID-19 Therapeutic EWG	Personal	NIL	N/A	N/A

Kenneth Baillie	COVID-19 Therapeutic EWG	Non- Personal	NIL	N/A	N/A
Kenneth Hodson	MWHEAG	Personal	NIL	N/A	N/A
Kenneth Hodson	MWHEAG	Non- Personal	NIL	N/A	N/A
Kevin Taylor	COVID-19 VBREWG, Cancer Vaccines EWG	Personal	NIL	N/A	N/A
Kevin Taylor	COVID-19 VBREWG, Cancer Vaccines EWG	Non- Personal	NIL	N/A	N/A
Kim Morley	Valproate Implementation EWG	Personal	NIL	N/A	N/A
Kim Morley	Valproate Implementation EWG	Non- Personal	NIL	N/A	N/A
Kimme Hyrich	COVID-19 VBREWG	Personal	NIL	N/A	N/A

Kimme Hyrich	COVID-19 VBREWG	Non- Personal	Abbvie	Education lecture at conference (fees paid to University of Manchester)	No
Kimme Hyrich	COVID-19 VBREWG	Non- Personal	Bristol Myers Squibb	Grant for rheumatoid arthritis research (for research unrelated to COVID-19)	Yes
Kimme Hyrich	COVID-19 VBREWG	Non- Personal	Pfizer	Grant for rheumatoid arthritis research (for research unrelated to COVID-19).	Yes
Kirstie Shearman	CTBVEAG	Personal	NIL	N/A	N/A
Kirstie Shearman	CTBVEAG	Non- Personal	NIL	N/A	N/A
Laurie Tomlinson	MWHEAG	Personal	NIL	N/A	N/A
Laurie Tomlinson	MWHEAG	Non- Personal	Bayer	I was an external consultant for a real-world evidence study about chronic kidney disease. Payment was to department.	No
Laurie Tomlinson	MWHEAG	Non- Personal	GSK	I participate in a collaboration between GSK and my department where they fund research PhD students and a post-doc to conduct research aimed at improving methodology for developing	Yes

				real-world evidence. I receive no personal payment.	
Laurie Tomlinson	MWHEAG	Non-Personal	GSK	I was a collaborator on a grant funded by GSK NCD OpenLAB aimed at investigating the prevalence of kidney disease in sub-Saharan Africa.	No
Lim Jones	IEAG	Personal	NIL	N/A	N/A
Lim Jones	IEAG	Conference / Scientific Meeting	Shionogi	One off fee for co-chairing educational conference.	No
Lim Jones	IEAG	Non-Personal	NIL	N/A	N/A
Lim Jones	IEAG	Additional			Whilst I have no current active role in any political party and was not active in any political party from January 2023 to December 2023, I have in the past held the elected role of Electoral Returning Officer for Wales Green Party and for Gwent Green Party. I have never had any paid post with any political party.
Linda Pepper	MWHEAG	Personal	NIL	N/A	N/A

Linda Pepper	MWHEAG	Non-Personal	NIL	N/A	N/A
Linda Pepper	MWHEAG	Additional			Public Governor with Northumbria Foundation NHS Trust to June 2024, Public Governor with Newcastle Foundation NHS Trust from June 2024, RCOG Lay Examiner with MRCOG exams
Lisa Brownell	NPPEAG	Personal	NIL	N/A	N/A
Lisa Brownell	NPPEAG	Non-Personal	NIL	N/A	N/A
Louis Grandjean	IEAG	Personal	Pfizer	Consultancy	Yes
Louis Grandjean	IEAG	Non-Personal	Pfizer	Support the organisation of the conference	Yes
Louise Massey	MWHEAG	Personal	NIL	N/A	N/A
Louise Massey	MWHEAG	Non-Personal	NIL	N/A	N/A
Louise Massey	MWHEAG	Additional			Member of the NICE guideline on Menopause Care. This affected one committee meeting in 2023 where I had to withhold

opinion about an agenda item regarding Mirena and Levosert. The document is now out for consultation with a final meeting on 29 and 30th January 2024. My understanding is therefore that this will be the end of this committee commitment.

Lucy Mackillop	MWH EAG	Personal	Sensyne Health plc	Shareholder	No
Lucy Mackillop	MWH EAG	Personal	Oxford University Innovation	Payment for royalties	Yes
Lucy Mackillop	MWH EAG	Personal	EMIS group plc	Salary and shareholder	Yes
Lucy Mackillop	MWH EAG	Non-Personal	NIL	N/A	N/A
Luigi (Gino) Martini	CPSEAG	Personal	GSK	Shares and pension	Yes
Luigi (Gino) Martini	CPSEAG	Personal	GSK, MSD, Becton Dickinson, Pinsent Masons, Knobbe Martin	Fees paid to own consultancy	Yes
Luigi (Gino) Martini	CPSEAG	Personal	Bioemolous Ltd	Fees paid to own consultancy	Yes

Luigi (Gino) Martini	CPSEAG	Personal	COLLTECH Labs	Shareholder	Yes
Luigi (Gino) Martini	CPSEAG	Personal	Biotherapy Services Ltd	Shareholder	Yes
Luigi (Gino) Martini	CPSEAG	Personal	Altabiome Therapeutics Ltd	Shareholder	Yes
Luigi (Gino) Martini	CPSEAG	Personal	Lakes Biosciences Ltd	Shareholder	Yes
Luigi (Gino) Martini	CPSEAG	Personal	Nash Therapeutics Ltd	Shareholder	Yes
Luigi (Gino) Martini	CPSEAG	Personal	GSK and SB	Immediate family member has shares	Yes
Luigi (Gino) Martini	CPSEAG	Non-Personal	GSK	Funded 2 PhD case awards	No
Luigi (Gino) Martini	CPSEAG	Non-Personal	Gamlen Tableting/ German Government	Funded fellowships to examine tableting	No
Luigi (Gino) Martini	CPSEAG	Non-Personal	Dr Reddys	Funded research programme	No
Luigi (Gino) Martini	CPSEAG	Non-Personal	Saudi Government	Funded PhD award	No

Luigi (Gino) Martini	CPSEAG	Non-Personal	Mexican Government	Funded PhD award	No
Ly-Mee Yu	Cancer Vaccines EWG	Personal	NIL	N/A	N/A
Ly-Mee Yu	Cancer Vaccines EWG	Non-Personal	NIL	N/A	N/A
Madeleine Wang	PEAG, COVID-19 VBREWG	Personal	NIL	N/A	N/A
Madeleine Wang	PEAG, COVID-19 VBREWG	Non-Personal	NIL	N/A	N/A
Majella Lane	CPSEAG	Personal	NIL	N/A	N/A
Majella Lane	CPSEAG	Non-Personal	NIL	N/A	N/A
Majella Lane	CPSEAG	Additional			
Marc Turner	CHM, CTBVEAG, Cancer Vaccines EWG, COVID-19 VBREWG,	Personal	NIL	N/A	N/A

I have established a consultancy company called Melderm Ltd. The company provides expert witness services for patent litigation cases in the United States.



Marc Turner	CHM, CTBVEAG, Cancer Vaccines EWG, COVID-19 VBREWG,	Non- Personal	NIL	N/A	N/A
Mark Evans	CDRRA EAG	Personal	Abbott Diabetes Care	Advisory board	Yes
Mark Evans	CDRRA EAG	Personal	NovoNordisk	Speakers fees	Yes
Mark Evans	CDRRA EAG	Personal	Eli Lilly	Speakers fees	Yes
Mark Evans	CDRRA EAG	Personal	Pila Pharma	Advisory board	Yes
Mark Evans	CDRRA EAG	Personal	Zucara	Advisory board	Yes
Mark Evans	CDRRA EAG	Personal	Dexcom	Advisory board	Yes
Mark Evans	CDRRA EAG	Conference /Scientific Meetings	Eli Lilly	UKCDF conference - Speaker and attendee (travel, registration and hotel costs)	Yes
Mark Evans	CDRRA EAG	Non- Personal	Abbott Diabetes Care	Research collaboration through EU Horizon 2020 project	Yes
Mark Evans	CDRRA EAG	Non- Personal	NovoNordisk	Research collaboration through EU Horizon 2020 project and a Case PhD studentship  Phase 3 triallist	Yes
Mark Evans	CDRRA EAG	Non- Personal	Imcyse	Triallist	Yes

Mark Evans	CDRRA EAG	Non-Personal	Novartis	Planned triallist	Yes
Mark Evans	CDRRA EAG	Non-Personal	ITB-Medical	Planned triallist	Yes
Martin Wilson	CHM, Valproate Implementation EWG	Personal	NIL	N/A	N/A
Martin Wilson	CHM, Valproate Implementation EWG	Non-Personal	NIL	N/A	N/A
Martin English	PMEAG	Personal	NIL	N/A	N/A
Martin English	PMEAG	Non-Personal	NIL	N/A	N/A
Matthias Schmid	IEAG	Personal	NIL	N/A	N/A
Matthias Schmid	IEAG	Non-Personal	NIL	N/A	N/A
Member1	Isotretinoin Implementation EWG	Personal	NIL	N/A	N/A

Member1	Isotretinoin Implementation EWG	Non-Personal	NIL	N/A	N/A
Member2	Isotretinoin Implementation EWG	Personal	Primary Care Dermatology Society	Author of the dermatology website <a href="http://www.pcds.org.uk">www.pcds.org.uk</a> , which includes acne guidelines	Yes
Member2	Isotretinoin Implementation EWG	Non-Personal	NIL	N/A	N/A
Member2	Isotretinoin Implementation EWG	Personal	Primary Care Dermatology Society	Author of the dermatology website <a href="http://www.pcds.org.uk">www.pcds.org.uk</a> , which includes acne guidelines	Yes
Member3	Isotretinoin Implementation EWG	Personal	NIL	N/A	N/A
Member3	Isotretinoin Implementation EWG	Non-Personal	NIL	N/A	N/A
Member3	Isotretinoin Implementation EWG	Additional			Co-editor of Rook's Textbook & Handbook of Dermatology for which I receive royalty payments.  Immediate past president of the British Association of Dermatologists

						Clinical Lead of NHS England Specialised Dermatology
						Clinical Director of NHSE Outpatients Recovery and Transformation
Member4	Isotretinoin Implementation EWG	Personal	Anathem Ltd	Cofounder and shareholder	Yes	
Member4	Isotretinoin Implementation EWG	Non- Personal	NIL	N/A	N/A	
Member4	Isotretinoin Implementation EWG	Additional				Anathem is ambient documentation software that undertakes administrative tasks for mental health clinicians. It is in product development stage and has made no sales.
Member5	Isotretinoin Implementation EWG	Personal	NIL	N/A	N/A	
Member5	Isotretinoin Implementation EWG	Non- Personal	NIL	N/A	N/A	

Member6	Isotretinoin Implementation EWG	Personal	NIL	N/A	N/A
Member6	Isotretinoin Implementation EWG	Non- Personal	NIL	N/A	N/A
Member7	Isotretinoin Implementation EWG	Personal	NIL	N/A	N/A
Member7	Isotretinoin Implementation EWG	Non- Personal	NIL	N/A	N/A
Member8	Valproate Epigenetics EWG	Personal	NIL	N/A	N/A
Member8	Valproate Epigenetics EWG	Non- Personal	NIL	N/A	N/A
Member9	Valproate Epigenetics EWG	Personal	NIL	N/A	N/A
Member9	Valproate Epigenetics EWG	Non- Personal	NIL	N/A	N/A

Member9	Valproate Epigenetics EWG	Additional				Named on patents in the area of epigenetic therapies.
Member10	Valproate Epigenetics EWG	Personal	NIL	N/A		N/A
Member10	Valproate Epigenetics EWG	Non-Personal	NIL	N/A		N/A
Member11	Valproate Implementation EWG	Personal	NIL	N/A		N/A
Member11	Valproate Implementation EWG	Conference /Scientific Meetings	UCB		Epilepsy Forum of Excellence: Honorarium for talk and accommodation/meals for meeting at which talk was given	No
Member11	Valproate Implementation EWG	Non-Personal	NIL	N/A		N/A
Member12	Valproate Implementation EWG	Personal	NIL	N/A		N/A
Member12	Valproate Implementation EWG	Conference /Scientific Meetings	UCB pharma		Forum of excellence - Conference attendance including, food and accommodation	No

Member12	Valproate Implementation EWG	Non-Personal	NIL	N/A	N/A
Member12	Valproate Implementation EWG	Additional			Have an interest in the safe prescribing of valproate and developed and led an audit on the topic which has been published: "Audit on neurologists' compliance with the MHRA guidance."
Michael Ardern-Jones	GRIDEAG	Personal	AbbVie	Consultancy, Speaker, Expenses, Advisory board fees	Yes
Michael Ardern-Jones	GRIDEAG	Personal	Almirall	Consultancy, Speaker, Expenses, Advisory board fees	No
Michael Ardern-Jones	GRIDEAG	Personal	Galderma	Consultancy, Speaker, Expenses, Advisory board fees	No
Michael Ardern-Jones	GRIDEAG	Personal	Janssen	Consultancy, Speaker, Expenses, Advisory board fees	No
Michael Ardern-Jones	GRIDEAG	Personal	Leo Pharma	Consultancy, Speaker, Expenses, Advisory board fees	Yes
Michael Ardern-Jones	GRIDEAG	Personal	Lilly	Consultancy, Speaker, Expenses, Advisory board fees	No
Michael Ardern-Jones	GRIDEAG	Personal	Novartis	Consultancy, Speaker, Expenses, Advisory board fees	No

Michael Ardern-Jones	GRIDEAG	Personal	Pfizer	Consultancy, Speaker, Expenses, Advisory board fees	Yes
Michael Ardern-Jones	GRIDEAG	Personal	Sanofi-Genzyme	Consultancy, Speaker, Expenses, Advisory board fees	No
Michael Ardern-Jones	GRIDEAG	Personal	Regeneron	Consultancy, Speaker, Expenses, Advisory board fees	Yes
Michael Ardern-Jones	GRIDEAG	Personal	UCB	Consultancy, Speaker, Expenses, Advisory board fees	Yes
Michael Ardern-Jones	GRIDEAG	Conference /Scientific Meetings	Sponsored by Janssen	American Academy of Dermatology Annual congress - Expenses	No
Michael Ardern-Jones	GRIDEAG	Conference /Scientific Meetings	Sponsored by Almirall	British Assoc Dermatology Annual congress - Expenses	No
Michael Ardern-Jones	GRIDEAG	Conference /Scientific Meetings	Sponsored by Galderma	European Academy of Dermato Venerology Annual Congress - Expenses	No
Michael Ardern-Jones	GRIDEAG	Non-Personal	Almirall	UHS Commercial clinical trial	No
Michael Ardern-Jones	GRIDEAG	Non-Personal	Abbvie	UHS Commercial clinical trial	No
Michael Ardern-Jones	GRIDEAG	Non-Personal	Leo Pharma	UHS Commercial clinical trial	No



Michael Ardern-Jones	GRIDEAG	Non-Personal	Amgen	UHS Commercial clinical trial	No	
Michael Ardern-Jones	GRIDEAG	Additional	Unilever			Biotechnology and Biological Sciences Research Council iCASE industrial studentships have been funded at my institution with Unilever. I supervised PhDs.
Michael Brown	IEAG	Personal	NIL	N/A	N/A	
Michael Brown	IEAG	Non-Personal	NIL	N/A	N/A	
Michael Jacobs	COVID-19 Therapeutic EWG, COVID-19 VBREWG	Personal	NIL	N/A	N/A	
Michael Jacobs	COVID-19 Therapeutic EWG, COVID-19 VBREWG	Non-Personal	NIL	N/A	N/A	
Michael Steiner	CDRRA EAG	Personal	NIL	N/A	N/A	
Michael Steiner	CDRRA EAG	Non-Personal	NIL	N/A	N/A	

Michael Threadgill	CPSEAG	Personal	NIL	N/A	N/A
Michael Threadgill	CPSEAG	Non-Personal	NIL	N/A	N/A
Morris Zwi	PMEAG	Personal	NIL	N/A	N/A
Morris Zwi	PMEAG	Non-Personal	NIL	N/A	N/A
Munir Pirmohamed	CHM, Cancer Vaccines EWG, COVID-19 Therapeutic EWG, COVID-19 VBREWG, RWD EWG	Personal	NIL	N/A	N/A
Munir Pirmohamed	CHM, Cancer Vaccines EWG, COVID-19 Therapeutic EWG, COVID-19 VBREWG, RWD EWG	Non-Personal	Astra Zeneca	Research grant to University of Liverpool (UoL), University of Manchester (UoM), University of Glasgow (UoG) and Queen Mary University London (QMUL) to support clinical fellowships jointly with UK Medical Research Council (MRC)	Yes
Munir Pirmohamed	CHM, Cancer Vaccines EWG, COVID-19 Therapeutic	Non-Personal	Eli Lilly	Research grant to University of Liverpool (UoL) to support clinical training fellowships	Yes

	EWG, COVID-19 VBREWG, RWD EWG			jointly with the Medical Research Council (MRC)	
Munir Pirmohamed	CHM, Cancer Vaccines EWG, COVID-19 Therapeutic EWG, COVID-19 VBREWG, RWD EWG	Non-Personal	Novartis	Research grant to UoL to support clinical training fellowships jointly with MRC	Yes
Munir Pirmohamed	CHM, Cancer Vaccines EWG, COVID-19 Therapeutic EWG, COVID-19 VBREWG, RWD EWG	Non-Personal	Roche	Research grant to UoL to support clinical training fellowships jointly with MRC	Yes
Munir Pirmohamed	CHM, Cancer Vaccines EWG, COVID-19 Therapeutic EWG, COVID-19 VBREWG, RWD EWG	Non-Personal	Simed Global	Advisor – no personal financial remuneration.	No
Munir Pirmohamed	CHM, Cancer Vaccines EWG, COVID-19 Therapeutic EWG, COVID-	Non-Personal	UCB Pharma	Research grant to UoL to support clinical training fellowships jointly with MRC	Yes

	19 VBREWG, RWD EWG				
Munir Pirmohamed	CHM, Cancer Vaccines EWG, COVID-19 Therapeutic EWG, COVID- 19 VBREWG, RWD EWG	Non- Personal	GSK	Research grant to University of Liverpool (UoL), University of Manchester (UoM), University of Glasgow (UoG) and Queen Mary University London (QMUL) to support clinical fellowships jointly with UK Medical Research Council (MRC)	Yes
Munir Pirmohamed	CHM, Cancer Vaccines EWG, COVID-19 Therapeutic EWG, COVID- 19 VBREWG, RWD EWG	Non- Personal	Optum Health	Research grant to University of Liverpool (UoL), University of Manchester (UoM), University of Glasgow (UoG) and Queen Mary University London (QMUL) to support clinical fellowships jointly with UK Medical Research Council (MRC)	
Munir Pirmohamed	CHM, Cancer Vaccines EWG, COVID-19 Therapeutic EWG, COVID- 19 VBREWG, RWD EWG	Non- Personal	Hammersmith Medicines Research	Research grant to University of Liverpool (UoL), University of Manchester (UoM), University of Glasgow (UoG) and Queen Mary University London (QMUL) to support clinical fellowships jointly with UK Medical Research Council (MRC)	

Munir  
Pirmohamed

CHM, Cancer  
Vaccines EWG,  
COVID-19  
Therapeutic  
EWG, COVID-  
19 VBREWG,  
RWD EWG

Additional

I am part of the IMI Consortium called ARDAT (<https://ardat.org/>). As is well known, this is partnership funding for research through the EU Commission, with academic partners like myself receiving funding via the EU (to the University of Liverpool), while Industry partners provide their expertise as an in-kind contribution. The companies involved in the IMI programme are: Pfizer, Bayer, Janssen Pharmaceutica NV, Lonza AG, Novartis, Novo Nordisk, Sanofi-Aventis, Spark Therapeutics, Inc., Takeda Pharmaceuticals International AG, Viscofan SA, Astellas Pharma Europe BV. These are declared as NP/NS when any of their products come up on the agenda.

Munir  
Pirmohamed

CHM, Cancer  
Vaccines EWG,  
COVID-19

Additional

I have been appointed as Chair of the Prix Galien UK

	Therapeutic EWG, COVID- 19 VBREWG, RWD EWG					prize awarding committee from September 2023.
Munir Pirmohamed	CHM, Cancer Vaccines EWG, COVID-19 Therapeutic EWG, COVID- 19 VBREWG, RWD EWG	Additional				I am a Medical Trustee for the British Heart Foundation, a member of the governing council of the Medical Research Council, and President of the Association of Physicians. I was also a Non-Executive Director for NHS England until 31 December 2023.
Naomi Fineberg	NPPEAG, Valproate Implementation EWG	Personal	NIL	N/A		N/A
Naomi Fineberg	NPPEAG, Valproate Implementation EWG	Conference /Scientific Meetings	British Association for Psychopharmac ology	British Association for Psychopharmacology public lecture – Expenses Paid		No
Naomi Fineberg	NPPEAG, Valproate Implementation EWG	Conference /Scientific Meetings	Children and Screens	Children and Screens Webinar - Honorarium		No

Naomi Fineberg	NPPEAG, Valproate Implementation EWG	Conference /Scientific Meetings	World Association for Stress and Anxiety Disorders (WASAD)	WASAD - Expenses	No
Naomi Fineberg	NPPEAG, Valproate Implementation EWG	Conference /Scientific Meetings	Italian Society for Biological Psychiatry	Italian Society for Biological Psychiatry - Expenses	No
Naomi Fineberg	NPPEAG, Valproate Implementation EWG	Conference /Scientific Meetings	European College of Neuropsychopharmacology (ECNP)	ECNP Annual Congress - Expenses	No
Naomi Fineberg	NPPEAG, Valproate Implementation EWG	Non-Personal	Biohaven	Corporate Membership fees were paid to the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS), a medical charity, of which I am the Secretary	Yes
Naomi Fineberg	NPPEAG, Valproate Implementation EWG	Additional			I work as a clinical lead of an NHS England Service providing pharmacological treatment for obsessive compulsive disorders. I act as an unpaid medical adviser and trustee to

			National Consumer Charities for OCD and related disorders.
Naomi Fineberg	NPPEAG, Valproate Implementation EWG	Additional	I chair the World Psychiatric Association Scientific section on anxiety, OCD and related disorders.
Naomi Fineberg	NPPEAG, Valproate Implementation EWG	Additional	I have contributed to the current British Association for Psychopharmacology (BAP) treatment guidelines for anxiety disorders (2014) and the NICE treatment guidelines including the most recent update (2013).
Naomi Fineberg	NPPEAG, Valproate Implementation EWG	Additional	I chair the external review board of the European College of Neuropsychopharmacology (ECNP).
Naomi Fineberg	NPPEAG, Valproate Implementation EWG	Additional	I am secretary of the International College of Obsessive-Compulsive spectrum Disorders (ICOCS), which has received corporate membership fees from Biohaven.



Naomi Fineberg	NPPEAG, Valproate Implementation EWG	Additional				I have received research grants from the NIHR and HORIZON 2020 (cost). I receive an honorarium from Elsevier for editorial duties for the Journal Comprehensive Psychiatry. I have received honoraria for educational lectures on diagnosis from the Global Mental Health Academy.
Naomi Fineberg	NPPEAG, Valproate Implementation EWG	Additional				I am a board member of the Consumer Charity Orchard (registered charity No: 1174480). I have received reimbursement for personal expenses for giving lectures at national and international meetings of various academic bodies in non-industry sponsored symposia.
Neil French	COVID-19 VBREWG	Personal	NIL	N/A	N/A	
Neil French	COVID-19 VBREWG	Personal	GlaxoSmithKline	Grant to institution with myself named as Principal Investigator	Yes	
Neil French	COVID-19 VBREWG	Personal	Seqirus	Grant to institution with myself named as Co-Investigator.	Yes	

Nidhi Sofat	GRIDEAG	Personal	NIL	N/A	N/A
Nidhi Sofat	GRIDEAG	Non-Personal	NIL	N/A	N/A
Nigel Klein	COVID-19 Therapeutic EWG, PMEAG	Personal	NIL	N/A	N/A
Nigel Klein	COVID-19 Therapeutic EWG, PMEAG	Non-Personal	NIL	N/A	N/A
Nigel Stallard	Cancer Vaccines EWG	Personal	NIL	N/A	N/A
Nigel Stallard	Cancer Vaccines EWG	Non-Personal	Novartis	PhD student sponsorship	Yes
Nigel Stallard	Cancer Vaccines EWG	Non-Personal	Janssen	PhD student sponsorship	Yes
Nigel Stallard	Cancer Vaccines EWG	Non-Personal	Novartis	Collaboration on grant application	Yes
Nigel Stallard	Cancer Vaccines EWG	Non-Personal	Roche	Collaboration on grant application	Yes
Nikoletta Fotaki	CPSEAG	Personal	NIL	N/A	N/A
Nikoletta Fotaki	CPSEAG	Non-Personal	NIL	N/A	N/A

Nikoletta Fotaki	CPSEAG	Additional				Director of Dr Fotaki BioPharm Consulting
Patricia McGettigan	PEAG	Personal	NIL	N/A	N/A	
Patricia McGettigan	PEAG	Non-Personal	NIL	N/A	N/A	
Patricia McGettigan	PEAG	Additional				I am an Independent Expert member of the European Medicines Agency Pharmacovigilance Risk Assessment Committee
Patrick Holmes	CDRRA EAG	Personal	Daichii-Sankyo	Speaker Fees	Yes	
Patrick Holmes	CDRRA EAG	Personal	Boehringer Ingelheim	Speaker Fees	Yes	
Patrick Holmes	CDRRA EAG	Personal	Abbott	Speaker Fee and Advisory Board	Yes	
Patrick Holmes	CDRRA EAG	Personal	Eli Lilly	Speaker Fees	Yes	
Patrick Holmes	CDRRA EAG	Personal	NovoNordisk	Advisory Board	Yes	
Patrick Holmes	CDRRA EAG	Personal	Bayer	Advisory Board	No	
Patrick Holmes	CDRRA EAG	Personal	AstraZeneca	Speaker Fees	Yes	
Patrick Holmes	CDRRA EAG	Personal	Menarini	Speaker Fees	Yes	

Patrick Holmes	CDRRA EAG	Non-Personal	NIL	N/A	N/A
Patrick Mark	CDRRA EAG	Personal	AstraZeneca	Consultancy	No
Patrick Mark	CDRRA EAG	Personal	Bayer	Lecture Fee, Consultancy	No
Patrick Mark	CDRRA EAG	Personal	Vifor	Consultancy	Yes
Patrick Mark	CDRRA EAG	Personal	AstraZeneca	Clinical Trial Steering Committee	No
Patrick Mark	CDRRA EAG	Personal	Pharmacosmos	Consultancy	No
Patrick Mark	CDRRA EAG	Personal	Novartis	Trial End Point Committee (blinded)	Yes
Patrick Mark	CDRRA EAG	Personal	Merck	Consultancy	No
Patrick Mark	CDRRA EAG	Non-Personal	NIL	N/A	N/A
Paul Dargan	CHM	Personal	NIL	N/A	N/A
Paul Dargan	CHM	Non-Personal	Janssen	I am the PI within my hospital. All funding for this study comes to my hospital.	Yes
Paul Dargan	CHM	Non-Personal	AstraZeneca	I was the PI within my hospital. All funding for this study came to my hospital.	Yes

Paul Dargan	CHM	Non-Personal	Moderna	I am the PI within my hospital. All funding for this study comes to my hospital.	
Paul Dargan	CHM	Non-Personal	Atea	UK Co-investigator. All funding for this study comes to my hospital.	Yes
Paul Dargan	CHM	Additional			I am the Chair of the Royal College of Emergency Medicine and National Poisons Information Service Antidote Guidelines Group which oversees advice to hospitals in England for the stocking of antidotes; I have Chaired this group since 2008. This group provides advice on the amount of antidote to be stocked by hospitals and the timeframe that the antidotes should be available. The advice is based on the published literature and there is no liaison with the pharmaceutical industry in relation to the guidance published by this group.
Paul Dargan	CHM	Additional			EAPCCT President Elect: I am President Elect of the

Paul Dargan

CHM

Additional

European Association of Poisons Control Centres and Clinical Toxicologists (EAPCCT: <http://www.eapcct.org/>) – my term as President will be 2024-2026. The EAPCCT is the European Clinical Toxicology Society and its main role is to organise the annual European Toxicology Conference “with the specific goal of advancing knowledge and understanding of the diagnosis and treatment of all forms of poisoning”.

I am an expert adviser on clinical toxicology to the World Health Organisation – this has predominantly involved advising on issues in relation to lead and mercury poisoning. I have contributed to WHO monographs and guidelines for lead and mercury poisoning.

Paul Dargan	CHM	Additional				I am on the Senior Editorial Board of Clinical Toxicology and the International Editorial Board of British Journal of Clinical Pharmacology.
Paul Lehner	COVID-19 VBREWG	Personal	NIL	N/A	N/A	
Paul Lehner	COVID-19 VBREWG	Non- Personal	NIL	N/A	N/A	
Peter Buckle	Cancer Vaccines EWG	Personal	NIL	N/A	N/A	
Peter Buckle	Cancer Vaccines EWG	Non- Personal	NIL	N/A	N/A	
Peter Hall	RWD EWG	Personal	NIL	N/A	N/A	
Peter Hall	RWD EWG	Non- Personal	AstraZeneca	Received Institutional research funding	Yes	
Peter Hall	RWD EWG	Non- Personal	Eisai	Received Institutional research funding	Yes	
Peter Hall	RWD EWG	Non- Personal	Roche	Received Institutional research funding	Yes	
Peter Hall	RWD EWG	Non- Personal	Lilly	Received Institutional research funding	Yes	

Peter Hall	RWD EWG	Non-Personal	AbbVie	Received Institutional research funding	Yes
Peter Hall	RWD EWG	Non-Personal	Novartis	Received Institutional research funding	Yes
Peter Hall	RWD EWG	Non-Personal	Merck	Received Institutional research funding	Yes
Peter Hall	RWD EWG	Non-Personal	Gilead	Received Institutional research funding	Yes
Peter Hall	RWD EWG	Non-Personal	Sanofi	Received Institutional research funding	Yes
Peter Hall	RWD EWG	Non-Personal	SeaGen	Received Institutional research funding	Yes
Philip Hannaford	MWHEAG	Personal	NIL	N/A	N/A
Philip Hannaford	MWHEAG	Non-Personal	NIL	N/A	N/A
Poulam Patel	CHM, OHEAG, Cancer Vaccines EWG	Personal	NIL	N/A	N/A
Poulam Patel	CHM, OHEAG, Cancer Vaccines EWG	Non-Personal	Astra Zeneca	Collaboration on research project and prospective phase 1 trial where AZ are providing drug to be added during	No



				preparation of dendritic cell vaccine	
Poulam Patel	CHM, OHEAG, Cancer Vaccines EWG	Non-Personal	BMS	Local PI for multicentre company sponsored trial	No
Poulam Patel	CHM, OHEAG, Cancer Vaccines EWG	Non-Personal	Merck	Local PI for multicentre company sponsored trial	No
Poulam Patel	CHM, OHEAG, Cancer Vaccines EWG	Non-Personal	Pfizer	Co-Investigator/Co-supervisor for translational research project into hepatotoxicity. Project part funded by educational grant from Pfizer	No
Poulam Patel	CHM, OHEAG, Cancer Vaccines EWG	Non-Personal	Pfizer	Local PI for multicentre company sponsored trial	No
Poulam Patel	CHM, OHEAG, Cancer Vaccines EWG	Non-Personal	Scancell	Co-supervisor for translational research project into hepatotoxicity. Project part funded by grant from Scancell	No
Poulam Patel	CHM, OHEAG, Cancer Vaccines EWG	Non-Personal	Scancell	Chief Investigator for company sponsored clinical trial	No
Poulam Patel	CHM, OHEAG, Cancer Vaccines EWG	Non-Personal	Scancell	Local PI for multicentre company sponsored trial	No

Rachel Tribe	MWH EAG	Personal	NIL	N/A	N/A
Rachel Tribe	MWH EAG	Non-Personal	Mirvie Inc., USA	Research grant	Yes
Rachel Tribe	MWH EAG	Additional			Some of my research benefits from my clinical collaborator's interactions with Hologic Inc. USA. I receive results originating the clinical collaborators use of the Hologic Quantitative fetal ibronectin test.
Ravishankar Sargur	GRIDEAG	Personal	NIL	N/A	N/A
Ravishankar Sargur	GRIDEAG	Non-Personal	NIL	N/A	N/A
Rebecca Kristeleit	OHEAG	Personal	Basilea	Consultancy	Yes
Rebecca Kristeleit	OHEAG	Personal	Amphista	Consultancy	Yes
Rebecca Kristeleit	OHEAG	Personal	Astra Zeneca	Consultancy	Yes
Rebecca Kristeleit	OHEAG	Personal	Clovis	Consultancy	Yes

Rebecca Kristeleit	OHEAG	Personal	Roche	Consultancy	Yes
Rebecca Kristeleit	OHEAG	Personal	GSK	Consultancy	Yes
Rebecca Kristeleit	OHEAG	Non-Personal	Various	Academic and Commercial Clinical Trial Programme with payments for trial work given to my Institution	Yes
Reecha Sofat	PEAG	Personal	Prescribed Medicines Code of Practice Authority	Member of Appeals Board	Yes
Reecha Sofat	PEAG	Non-Personal	NIL	N/A	N/A
Rhian Thomas-Turner	PMEAG	Personal	NIL	N/A	N/A
Rhian Thomas-Turner	PMEAG	Non-Personal	Sanofi	Grant to NHS for research time for participating in study. Per patient funding through NIHR costing template	Yes
Rhian Thomas-Turner	PMEAG	Non-Personal	Astellas	Participating in commercial trial PP funding through NIHR costing template	Yes

Rhian Thomas-Turner	PMEAG	Non-Personal	Vertex	Participating in commercial trial PP funding through NIHR costing template	Yes
Rhian Thomas-Turner	PMEAG	Non-Personal	Medtronic	Participating in commercial trial PP funding through NIHR costing template	Yes
Rhian Thomas-Turner	PMEAG	Non-Personal	Noema Pharma	Participating in commercial trial PP funding through NIHR costing template	Yes
Rhian Thomas-Turner	PMEAG	Non-Personal	Amgen	Participating in commercial trial PP funding through NIHR costing template	Yes
Rhian Thomas-Turner	PMEAG	Non-Personal	Sobi Pharma	Participating in commercial trial PP funding through NIHR costing template	Yes
Rhian Thomas-Turner	PMEAG	Non-Personal	Moderna	Participating in commercial trial PP funding through NIHR costing template	Yes
Rhian Thomas-Turner	PMEAG	Non-Personal	Efpia	None-sponsorship allowed event to take place but no direct benefit to self	No
Rhian Thomas-Turner	PMEAG	Non-Personal	Sanofi	None-sponsorship allowed event to take place but no direct benefit to self	No

Rhian Thomas-Turner	PMEAG	Non-Personal	Roche	None-sponsorship allowed event to take place but no direct benefit to self	No
Rhian Thomas-Turner	PMEAG	Non-Personal	Novartis	None-sponsorship allowed event to take place but no direct benefit to self	No
Rhian Thomas-Turner	PMEAG	Non-Personal	AstraZeneca	None-sponsorship allowed event to take place but no direct benefit to self	No
Rhian Thomas-Turner	PMEAG	Non-Personal	Pfizer	None-sponsorship allowed event to take place but no direct benefit to self	No
Rhian Thomas-Turner	PMEAG	Non-Personal	Apartio	None-sponsorship allowed event to take place but no direct benefit to self	No
Rhian Thomas-Turner	PMEAG	Non-Personal	Takeda	Participating in commercial trial PP funding through NIHR costing template	Yes
Richard Fitzgerald	PEAG	Personal	NIL	N/A	N/A
Richard Fitzgerald	PEAG	Non-Personal	NIL	N/A	N/A
Richard Gilson	CHM, COVID-19 Therapeutic EWG, IEAG	Personal	NIL	N/A	N/A

Richard Gilson	CHM, COVID-19 Therapeutic EWG, IEAG	Non-Personal	Gilead Sciences	My department is a collaborating site in clinical trials sponsored by Gilead Sciences, who have provided research funds to the department (Central and North West London NHS Foundation Trust). I have been a local principal investigator and sub-investigator for trials sponsored Gilead Sciences.	Yes
Richard Gilson	CHM, COVID-19 Therapeutic EWG, IEAG	Non-Personal	GSK	My department is a collaborating site in clinical trials sponsored by GSK, who have provided research funds to the department (received by Central and North West London NHS Foundation Trust). I have been local principal investigator for trials sponsored GSK.	Yes
Richard Gilson	CHM, COVID-19 Therapeutic EWG, IEAG	Non-Personal	Janssen	My department is a collaborating site in clinical trials sponsored by Janssen, who have provided research funds to the department (Central and North West London NHS Foundation Trust)	Yes

Richard Gilson	CHM, COVID-19 Therapeutic EWG, IEAG	Non-Personal	Merck	My department is a collaborating site in clinical trials sponsored by Merck, who have provided research funds to the department (Central and North West London NHS Foundation Trust)	Yes
Richard Gilson	CHM, COVID-19 Therapeutic EWG, IEAG	Non-Personal	Pfizer	My department is a collaborating site in clinical trials sponsored by Pfizer, who have provided research funds to the department (received by UCL and by Central and North West London NHS Foundation Trust)	Yes
Richard Gilson	CHM, COVID-19 Therapeutic EWG, IEAG	Non-Personal	ViiV	My department is a collaborating site in clinical trials sponsored by ViiV, who have provided research funds to the department (received by UCL and by Central and North London NHS Foundation Trust)	Yes
Richard Gilson	CHM, COVID-19 Therapeutic EWG, IEAG	Additional			Members of the UCL Institute for Global Health are investigators or sub-investigators on trials of COVID vaccines and antiviral therapies. I have not been directly involved in

these studies, except for one study of an antiviral product from Gilead Sciences on which I was a sub-investigator. I was the interim director of the Institute for Global Health and therefore had overall responsibility for the research undertaken in the Institute.

Robert Andrews	Cancer Vaccines EWG	Personal	NIL	N/A	N/A
Robert Andrews	Cancer Vaccines EWG	Non-Personal	NIL	N/A	N/A
Robert Brown	Cancer Vaccines EWG	Personal	NIL	N/A	N/A
Robert Brown	Cancer Vaccines EWG	Non-Personal	NIL	N/A	N/A
Robert Brown	Cancer Vaccines EWG	Additional			
Robert Lowe	CPSEAG, Cancer Vaccines EWG	Personal	NIL	N/A	N/A

Named on patents in the area of epigenetic therapies.



Robert Lowe	CPSEAG, Cancer Vaccines EWG	Non- Personal	NIL	N/A	N/A
Robin Thorpe	CTBVEAG, Cancer Vaccines EWG COVID-19 VBREWG	Personal	NIL	N/A	N/A
Robin Thorpe	CTBVEAG, Cancer Vaccines EWG COVID-19 VBREWG	Non- Personal	NIL	N/A	N/A
Rod Mitchell	Valproate Epigenetics EWG	Personal	NIL	N/A	N/A
Rod Mitchell	Valproate Epigenetics EWG	Non- Personal	NIL	N/A	N/A
Ruben Thanacoody	PEAG	Personal	NIL	N/A	N/A
Ruben Thanacoody	PEAG	Non- Personal	NIL	N/A	N/A
Rubin Minhas	PMEAG	Personal	NIL	N/A	N/A

Rubin Minhas	PMEAG	Non-Personal	NIL	N/A	N/A
Rubin Minhas	PMEAG	Additional			A member of political party.
Rui Providencia	CHM	Personal	NIL	N/A	N/A
Rui Providencia	CHM	Non-Personal	Biosense Webster (Johnson and Johnson)	Principal Investigation Research grant for PhD student	Yes
Rupert Payne	PEAG	Personal	NIL	N/A	N/A
Rupert Payne	PEAG	Non-Personal	NIL	N/A	N/A
Rupert Payne	PEAG	Additional			I receive freelance payment as consultant editor for Prescriber magazine (Wiley publishers) which carries advertising for the pharmaceutical industry. I have no involvement in the advertising side of the publication. I have received funding for primary care research from NIHR, MRC and Wellcome Trust. This is not specific to

						any particular pharmaceutical product.
Ruth Paulin	CPSEAG	Personal	NIL	N/A	N/A	
Ruth Paulin	CPSEAG	Non-Personal	NIL	N/A	N/A	
Sandosh Padmanabhan	CHM, CDRRA EAG	Personal	NIL	N/A	N/A	
Sandosh Padmanabhan	CHM, CDRRA EAG	Non-Personal	NIL	N/A	N/A	
Sandosh Padmanabhan	CHM, CDRRA EAG	Additional				Founder shares from Kvatchii Limited (non-pharmaceutical)
Sara Payne	Isotretinoin Implementation EWG	Personal	NIL	N/A	N/A	
Sara Payne	Isotretinoin Implementation EWG	Non-Personal	PHG Foundation (Cambridge)	Associate (P/T)	Yes	
Sara Payne	Isotretinoin Implementation EWG	Non-Personal	NICE - Highly Specialised Technology Evaluation Committee	Lay member	Yes	
Sarah Meredith	RWD EWG	Personal	NIL	N/A	N/A	

Sarah Meredith	RWD EWG	Non-Personal	Johnson & Johnson	Grant funding for trial for which I am an investigator	Yes
Sarah Wild	CDRRA EAG	Personal	NIL	N/A	N/A
Sarah Wild	CDRRA EAG	Non-Personal	NIL	N/A	N/A
Shahida Din	GRID	Personal	Ferring	Speaker Fees	No
Shahida Din	GRID	Personal	AbbVie	Speaker Fee	No
Shahida Din	GRID	Conference /Scientific Meetings	Janssen	European Crohn's & Colitis Annual Meeting - Flights, Accommodation, Symposium Registration Fees	No
Shahida Din	GRID	Conference /Scientific Meetings	Dr Falk	Dr Falk Symposium Potsdam Mucosal Immunology – Flights, Accommodation, Symposium Registration Fees	No
Shahida Din	GRID	Non-Personal	Edinburgh & Lothian Health Foundations Award	Research Funding	Yes
Shahida Din	GRID	Non-Personal	Pathological Society of Great Britain & Northern Ireland	Research Funding	Yes

Shahida Din	GRID	Non-Personal	Helmsley Charitable Trust Disease	Research Funding	Yes	
Shahida Din	GRID	Additional				Collaborator for Clinical Trial (Principal Investigator) - Funder John Moulton Foundation, Sponsor NHS Lothian/University of Edinburgh
Shahida Din	GRID	Additional				British Society of Gastroenterology, Inflammatory Bowel Disease Section Committee Member
Shahida Din	GRID	Additional				Royal College of Physicians of Edinburgh, Gastroenterology Specialty Advisor
Shahida Din	GRID	Additional				Scottish Government, Lead for Inflammatory Bowel Disease - Cancer Surveillance
Shirley Price	PMEAG, Cancer Vaccines EWG, Isotretinoin Implementation EWG, COVID-19 Therapeutics EWG, COVID-19	Personal	NIL	N/A	N/A	

	VBREWG, Valproate Epigenetics EWG				
Shirley Price	PMEAG, Cancer Vaccines EWG, Isotretinoin Implementation EWG, COVID-19 Therapeutics EWG, COVID-19 VBREWG, Valproate Epigenetics EWG	Non- Personal	AstraZeneca	Yes	Yes
Shirley Price	PMEAG, Cancer Vaccines EWG, Isotretinoin Implementation EWG, COVID-19 Therapeutics EWG, COVID-19 VBREWG, Valproate Epigenetics EWG	Non- Personal	GSK	Yes	Yes
Shirley Price	PMEAG, Cancer Vaccines EWG, Isotretinoin	Non- Personal	ApconiX	Donation to the British Toxicology Society of which I am a Trustee for general	No

	Implementation EWG, COVID-19 Therapeutics EWG, COVID-19 VBREWG, Valproate Epigenetics EWG			support of the Annual Congress.	
Shuaib Nasser	CDRRA EAG	Personal	AZ	Consultancy and lecture	Yes
Shuaib Nasser	CDRRA EAG	Personal	ALK	Consultancy and lecture	Yes
Shuaib Nasser	CDRRA EAG	Non- Personal	NIL	N/A	N/A
Simon Drysdale	PMEAG	Personal	NIL	N/A	N/A
Simon Drysdale	PMEAG	Non- Personal	Sanofi Pasteur, Merck, Valneva, Pfizer, Janssen, Moderna, ILiAD, Astra Zeneca	I have been a local PI or national CI for multiple research studies for multiple pharmaceutical companies. All funds have been paid to my institution and I have received no personal fees.	Yes
Simon Drysdale	PMEAG	Additional			Immediate family member works in the same academic department and has worked on many of the same and other studies. They received no personal fees for any of

these studies, all funds are paid to the institution.

Simon Drysdale	PMEAG	Additional				Member of the JCVI RSV subcommittee
Siow Ming Lee	PMEAG	Personal	NIL	N/A		N/A
Siow Ming Lee	PMEAG	Conference / Scientific Meetings	Takeda	2023 ESMO - Conference attendance		No
Siow Ming Lee	PMEAG	Non-Personal	NIL	N/A		N/A
Siow Ming Lee	PMEAG	Additional				Global Chief Investigator: Randomised phase 3 trial of atezolizumab to treat advanced lung cancer with poor performance status Chief Investigator: Randomised trial of high dose hydroxychloroquine in combination with chemotherapy to treat patients with metastatic small cell lung cancer
Siraj Misbah	COVID-19 Therapeutics EWG, COVID-19 VBREWG,	Personal	NIL	N/A		N/A



Siraj Misbah	COVID-19 Therapeutics EWG, COVID-19 VBREWG,	Non-Personal	NIL	N/A	N/A
Stella O'Brien	IEAG	Personal	NIL	N/A	N/A
Stella O'Brien	IEAG	Non-Personal	NIL	N/A	N/A
Steven Cunningham	CHM, PMEAG, Isotretinoin Implementation EWG	Personal	NIL	N/A	N/A
Steven Cunningham	CHM, PMEAG, Isotretinoin Implementation EWG	Non-Personal	Gilead	Bronchiolitis RSV antiviral trial development. Fees paid to University of Edinburgh.	Yes
Steven Cunningham	CHM, PMEAG, Isotretinoin Implementation EWG	Non-Personal	ArkBiosciences	Bronchiolitis RSV antiviral trial development. Fees paid to University of Edinburgh.	Yes
Steven Cunningham	CHM, PMEAG, Isotretinoin Implementation EWG	Non-Personal	Vertex	Local PI for ARRIVAL study (VX15-770-124/126)	No
Steven Cunningham	CHM, PMEAG, Isotretinoin	Non-Personal	Inhalon	Bronchiolitis RSV antiviral trial development. Employer fees paid to University of Edinburgh.	Yes

	Implementation EWG					
Steven Cunningham	CHM, PMEAG, Isotretinoin Implementation EWG	Non- Personal	Pfizer	Bronchiolitis RSV antiviral trial development. Fees paid to University of Edinburgh.	Yes	
Steven Cunningham	CHM, PMEAG, Isotretinoin Implementation EWG	Non- Personal	GSK	Local PI for maternal RSV vaccine study	Yes	
Steven Cunningham	CHM, PMEAG, Isotretinoin Implementation EWG	Non- Personal	Boehringer Ingelheim	Trial steering committee with employer fees paid to the University of Edinburgh.	Yes	
Steven Cunningham	CHM, PMEAG, Isotretinoin Implementation EWG	Non- Personal	Shionogi	Bronchiolitis RSV antiviral trial development. Employer fees paid to University of Edinburgh.	No	
Steven Cunningham	CHM, PMEAG, Isotretinoin Implementation EWG	Additional				Chair of the UK Cystic Fibrosis Trust Registry Research Committee. Within this role I have oversight role for the Post Authorisation Safety Study of Ivacaftor in children aged 2-5 years. Edinburgh University

Steven Cunningham	CHM, PMEAG, Isotretinoin Implementation EWG	Additional				receives payment for my time in this role.
Stuart Ralston	GRIDEAG, MWHEAG	Personal	NIL	N/A	N/A	
Stuart Ralston	GRIDEAG, MWHEAG	Non-Personal	Abbvie Alexion Amgen Bristol Myers-Squibb Celgene	Support for scientific meeting	No	
Stuart Ralston	GRIDEAG, MWHEAG	Non-Personal	Consilient Health Janssen Eli-Lilly Novartis Pfizer	Support for scientific meeting	No	

Stuart Ralston	GRIDEAG, MWHEAG	Non- Personal	Roche Sandoz Sanofi-Genzyme Thornton & Ross UCB	Support for scientific meeting	No	
Stuart Ralston	GRIDEAG, MWHEAG	Non- Personal	AstraZeneca	Support for recruiting patients into a clinical registry study	Yes	
Stuart Ralston	GRIDEAG, MWHEAG	Non- Personal	Kyowa Kirin	Support for recruiting patients into a clinical registry study	Yes	
Stuart Ralston	GRIDEAG, MWHEAG	Non- Personal	Eli Lilly	Donation of Teriparatide for a clinical trial	Yes	
Stuart Ralston	GRIDEAG, MWHEAG	Non- Personal	Kyowa Kirin	Consultancy to Employer	Yes	
Stuart Ralston	GRIDEAG, MWHEAG	Additional				External examiner for Oxford University Clinical trials MSc course
Susan Bradford	CHM, IEAG, COVID-19 Therapeutics EWG, RWD EWG	Personal	NIL	N/A	N/A	
Susan Bradford	CHM, IEAG, COVID-19 Therapeutics	Non- Personal	NIL	N/A	N/A	

	EWG, RWD EWG					
Susan Hopkins	IEAG	Personal	NIL	NIL		N/A
Susan Hopkins	IEAG	Non- Personal	NIL	NIL		N/A
Susan Hunneyball	PEAG, COVID- 19 VBREWG	Personal	NIL	N/A		N/A
Susan Hunneyball	PEAG, COVID- 19 VBREWG	Non- Personal	NIL	N/A		N/A
Susan Hunneyball	PEAG, COVID- 19 VBREWG	Additional				Writes articles published in the Chemist and Druggist magazine, a trade magazine for pharmacists but receives no payment for those articles. The information referred to is in the public domain. Ms Hunneyball makes it clear that these are her personal views and reflections and references all sources of information used.
Susannah Walsh	CPSEAG, COVID-19 VBREWG	Personal	Techfest	Director		Yes

Susannah Walsh	CPSEAG, COVID-19 VBREWG	Personal	University of Reading	External examiner	Yes
Susannah Walsh	CPSEAG, COVID-19 VBREWG	Personal	University of Wolverhampton	External examiner	Yes
Susannah Walsh	CPSEAG, COVID-19 VBREWG	Personal	Kingston University	External examiner	Yes
Susannah Walsh	CPSEAG, COVID-19 VBREWG	Personal	Better Vision Solutions	Consultancy and licence agreement for technology. Named on patents.	Yes
Susannah Walsh	CPSEAG, COVID-19 VBREWG	Personal	DSTL	Research grant. Named on DMU patents associated with grant	Yes
Susannah Walsh	CPSEAG, COVID-19 VBREWG	Personal	DEB	Research grant. Named on DMU patents associated with grant	Yes
Susannah Walsh	CPSEAG, COVID-19 VBREWG	Personal	Reckitt Benckiser	Commercial contract. Named on DMU patents associated with contract.	Yes
Susannah Walsh	CPSEAG, COVID-19 VBREWG	Personal	PAL	Research collaboration and MTA. Named on DMU patents associated with work.	Yes

Susannah Walsh	CPSEAG, COVID-19 VBREWG	Personal	Chemical Biologic Center of Combat Capabilities Development Command and Defence Threat Reduction Agency	Research collaboration and MTA. Named on DMU patents associated with work.	Yes
Susannah Walsh	CPSEAG, COVID-19 VBREWG	Personal	Safer Disinfectant Network	I have attended some online meetings involving academics and disinfection companies run by the Safer Disinfectant Network. I have not attended a meeting for more than a year and am not sure if this organisation is still active. I have no personal links to the companies who are signed up to their charter (to promote best practice and support public health in the workplace) beyond those detailed above.	Yes
Susannah Walsh	CPSEAG, COVID-19 VBREWG	Non-Personal	NIL	N/A	N/A
Tejal Mitchell	Valproate Implementation EWG	Personal	NIL	N/A	N/A

Tejal Mitchell	Valproate Implementation EWG	Conference /Scientific Meeting	Angelini Pharma	35th International Epilepsy Congress: Expenses	No
Tejal Mitchell	Valproate Implementation EWG	Conference /Scientific Meeting	UCB Pharma	Epilepsy Forum of Excellence: Expenses	No
Tejal Mitchell	Valproate Implementation EWG	Non-Personal	NIL	N/A	N/A
Theresa McDonagh	CDRRA EAG	Personal	Astra Zeneca	Consultancy	No
Theresa McDonagh	CDRRA EAG	Personal	Edwards	Consultancy and Speaker fee	No
Tess McPherson	Isotretinoin Implementation EWG	Personal	NIL	N/A	N/A
Tess McPherson	Isotretinoin Implementation EWG	Non-Personal	NIL	N/A	N/A
Theresa McDonagh	CDRRA EAG	Personal	Boehringer Ingelheim	Consultancy	No
Theresa McDonagh	CDRRA EAG	Non-Personal	NIL	N/A	N/A



Timothy Gant	Valproate Epigenetics EWG	Personal	NIL	N/A	N/A
Timothy Gant	Valproate Epigenetics EWG	Non-Personal	NIL	N/A	N/A
Timothy Gant	Valproate Epigenetics EWG	Additional			Co-editor on Toxicology Letters (Elsevier)
Tom Clutton-Brock	Cancer Vaccines EWG	Personal	NIL	N/A	N/A
Tom Clutton-Brock	Cancer Vaccines EWG	Non-Personal	NIL	N/A	N/A
Tony Jamieson	Valproate Implementation EWG	Personal	NIL	N/A	N/A
Tony Jamieson	Valproate Implementation EWG	Non-Personal	NIL	N/A	N/A
Vanessa Raymont	CHM, Valproate Implementation EWG	Personal	NIL	N/A	N/A
Vanessa Raymont	CHM, Valproate	Non-Personal	Janssen	Offer of potential funding for research study mainly funded	Yes

	Implementation EWG			by Medical Research Council grant for which I am Chief Investigator	
Vanessa Raymont	CHM, Valproate Implementation EWG	Non- Personal	Lilly	Staffing costs provided via a Collaborative Working Agreement to do a pilot project to expand CSF testing in NHS memory clinics for which I am Chief Investigator	Yes
V'lain Fenton- May	COVID-19 VBREWG, CPSEAG	Personal	NIL	N/A	N/A
V'lain Fenton- May	COVID-19 VBREWG, CPSEAG	Non- Personal	NIL	N/A	N/A
Wajid Hussain	CDRRA EAG	Personal	NIL	N/A	N/A
Wajid Hussain	CDRRA EAG	Conference /Scientific Meetings	Bayer Pharmaceuticals	Bayer Cardiovascular Summit – Speaker fee	No
Wajid Hussain	CDRRA EAG	Non- Personal	NIL	N/A	N/A
Waqar Rashid	NPPEAG	Personal	NIL	N/A	N/A
Waqar Rashid	NPPEAG	Non- Personal	NIL	N/A	N/A

William Herrington	CDRRA EAG	Personal	NIL	N/A	N/A
William Herrington	CDRRA EAG	Non-Personal	Boehringer Ingelheim & Eli Lilly	Grant holder of grant from university to design and conduct the EMPA-Kidney trial	Yes
William Herrington	CDRRA EAG	Non-Personal	Boehringer Ingelheim	Grant holder of grant from university to design and conduct the EASI-Kidney trial	Yes
William John Watkins	PMEAG	Personal	NIL	N/A	N/A
William John Watkins	PMEAG	Non-Personal	NIL	N/A	N/A
Yvonne Perrie	CHM, CPSEAG, COVID-19 VBREWG, Cancer Vaccines EWG	Personal	NIL	N/A	N/A
Yvonne Perrie	CHM, CPSEAG, COVID-19 VBREWG, Cancer Vaccines EWG	Non-Personal	CURIA	Knowledge exchange research contracts from company to University of Strathclyde and joint PhD funding.	No
Yvonne Perrie	CHM, CPSEAG, COVID-19 VBREWG,	Non-Personal	Imperial College London	Research Contract with CRUK Formulation Unit based within UoS.	No

Cancer Vaccines EWG					
Yvonne Perrie	CHM, CPSEAG, COVID-19 VBREWG, Cancer Vaccines EWG	Non- Personal	Imperial College London	Research Collaborator: Wellcome Leap Grant to University of Strathclyde.	No
Yvonne Perrie	CHM, CPSEAG, COVID-19 VBREWG, Cancer Vaccines EWG	Non- Personal	Microfluidics Inc	Equipment loan to University of Strathclyde and in-kind research support (consumables).	No
Yvonne Perrie	CHM, CPSEAG, COVID-19 VBREWG, Cancer Vaccines EWG	Non- Personal	Avanti polar lipids/CRODA	BBSRC Icase PhD studentship grant to University of Strathclyde	No
Yvonne Perrie	CHM, CPSEAG, COVID-19 VBREWG, Cancer Vaccines EWG	Non- Personal	Precisions Nanosystems Inc	Knowledge exchange research contracts from company to University of Strathclyde and joint PhD funding.	No
Yvonne Perrie	CHM, CPSEAG, COVID-19 VBREWG, Cancer Vaccines EWG	Non- Personal	AstraZeneca	Equipment loan to University of Strathclyde to support project.	No

Yvonne Perrie	CHM, CPSEAG, COVID-19 VBREWG, Cancer Vaccines EWG	Non-Personal	Defence Threat Reduction Agency DTRA (administered by DSTL)	PhD studentships including lcase.	No
Yvonne Perrie	CHM, CPSEAG, COVID-19 VBREWG, Cancer Vaccines EWG	Non-Personal	Janssen Pharmaceutica	Research Grant to University of Strathclyde	No
Yvonne Perrie	CHM, CPSEAG, COVID-19 VBREWG, Cancer Vaccines EWG	Non-Personal	Target Healthcare	Research Grant to University of Strathclyde	No
Yvonne Perrie	CHM, CPSEAG, COVID-19 VBREWG, Cancer Vaccines EWG	Non-Personal	Takeda / Millenium Pharmaceuticals	Knowledge Transfer Partnership research Grant to University of Strathclyde	No
Yvonne Perrie	CHM, CPSEAG, COVID-19 VBREWG, Cancer Vaccines EWG	Non-Personal	LEON Nano Drugs GmbH	Knowledge exchange research contracts from company to University of Strathclyde	No

Yvonne Perrie	CHM, CPSEAG, COVID-19 VBREWG, Cancer Vaccines EWG	Non-Personal	Stablepharma Ltd	Knowledge exchange research contracts from company to University of Strathclyde	No
Yvonne Perrie	CHM, CPSEAG, COVID-19 VBREWG, Cancer Vaccines EWG	Non-Personal	Precision Nanomedicines Inc	Knowledge exchange research contracts from company to University of Strathclyde	No
Yvonne Perrie	CHM, CPSEAG, COVID-19 VBREWG, Cancer Vaccines EWG	Non-Personal	NOF CORPORATION	Knowledge exchange research contracts from company to University of Strathclyde and joint PhD funding.	No
Yvonne Perrie	CHM, CPSEAG, COVID-19 VBREWG, Cancer Vaccines EWG	Non-Personal	Veterna Srl	Equipment loan to University of Strathclyde to support project."	No
Yvonne Perrie	CHM, CPSEAG, COVID-19 VBREWG, Cancer Vaccines EWG	Non-Personal	Carocell Bio Limited	Knowledge exchange research contracts from company to University of Strathclyde	No

Yvonne Perrie	CHM, CPSEAG, COVID-19 VBREWG, Cancer Vaccines EWG	Non-Personal	SixFold	Knowledge exchange research contracts from company to University of Strathclyde	No
Yvonne Perrie	CHM, CPSEAG, COVID-19 VBREWG, Cancer Vaccines EWG	Non-Personal	Micropore Technologies Ltd	Knowledge exchange research contracts from company to University of Strathclyde	No
Yvonne Perrie	CHM, CPSEAG, COVID-19 VBREWG, Cancer Vaccines EWG	Non-Personal	pHion	Knowledge exchange research contracts from company to University of Strathclyde	
Yvonne Perrie	CHM, CPSEAG, COVID-19 VBREWG, Cancer Vaccines EWG	Non-Personal	ABITEC	Knowledge exchange research contracts from company to University of Strathclyde and joint PhD funding. Equipment loan to University of Strathclyde. Innovate UK grant.	
Yvonne Perrie	CHM, CPSEAG, COVID-19 VBREWG, Cancer Vaccines EWG	Non-Personal	Centre for process Innovation Ltd	Innovate UK grant to University of Strathclyde	
Yvonne Perrie	CHM, CPSEAG, COVID-19	Additional			Conference chair for Liposome Research Days

VBREWG,  
Cancer Vaccines  
EWG

Yvonne Perrie    CHM, CPSEAG,    Additional  
                         COVID-19  
                         VBREWG,  
                         Cancer Vaccines  
                         EWG

2024. I am the conference chair for LRD2024 which is being hosted by the University of Strathclyde and sponsored by a range of companies. I am doing this within my role in the University and will receive no additional payments as conference chair. All finances are managed by the University of Strathclyde. This was previously discussed with MHRA and confirmed to be no Col.

Head of Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS). We are an internationally leading technological University and as such we work with many companies across the dept, faculty and University. We also work with Health care providers including a wide range of NHS trusts and pharmacies through both research and education.





**Contact information about these reports:**

Medicines and Healthcare products Regulatory Agency  
Customer Services  
10 South Colonnade  
Canary Wharf  
London E14 4PU

Tel: 020 3080 6000

E-mail: [info@mhra.gov.uk](mailto:info@mhra.gov.uk)

© Crown copyright 2024

Published by the Medicine and Healthcare products Regulatory Agency

ISBN 978-1-8384147-3-3

Guidance on reproducing and re-using MHRA Crown copyright material can be found on our website at:  
<http://www.nationalarchives.gov.uk/information-management/re-using-public-sector-information/copyright-and-re-use/crown-copyright/>

**An application for permission to reproduce MHRA material.**